top of page
SBC logo .png

SurvivingBreastCancer.org

Search this site

882 results found with an empty search

  • Living With the “What If”: Fear of Recurrence and Fear of Progression

    Why the fear shows up, what sets it off, and what the research says actually helps. A headache that lingers a day too long. A scan date circled on the calendar. A friend’s news that hits a little too close to home. For many people touched by breast cancer, moments like these bring a familiar question rushing back: What if it’s back? What if it’s growing? What if the drugs are not working? By Laura Carfang, Ed.D. EDUCATION | MENTAL HEALTH Key Takeaways More than half of cancer survivors experience at least moderate fear of recurrence, and about 1 in 5 experience high levels. Fear of progression in metastatic breast cancer is a distinct experience that calls for different support. Common triggers include scans, new symptoms, anniversaries, and other people’s cancer stories. Cognitive behavioral therapy, mindfulness, and structured programs like ConquerFear have been shown in randomized trials to reduce fear of recurrence. ASCO recommends regular screening for anxiety and depression, and you can ask your care team for support at any time. Two Fears, Two Different Realities Fear of recurrence is the worry that cancer will return after treatment for early-stage breast cancer. It’s one of the most common concerns survivors report. A large international analysis of more than 9,000 people found that about 59% of cancer survivors and patients experience at least moderate fear of recurrence, and about 1 in 5 experience high levels. Women and younger people tend to report more. Fear of progression is the worry that metastatic breast cancer (MBC) will grow, spread, or stop responding to treatment. Researchers increasingly see it as its own experience, not just a version of fear of recurrence. People living with MBC aren’t waiting to find out if cancer will change. They’re living with a disease that needs ongoing treatment, and the uncertainty looks different. Both fears are normal responses to a very real experience. They become a problem when they start crowding out sleep, relationships, plans, or joy. The good news is that there are proven ways to turn the volume down. Understanding Your Fear Triggers Fear rarely arrives out of nowhere. It usually has a trigger, something that reminds the brain of danger. Knowing yours won’t make the fear disappear, but it can make it feel less like an ambush. Common triggers include: • Medical moments: upcoming scans, waiting for results (often called “scanxiety”), routine checkups, or a change in your treatment plan. • Body signals: a new ache, cough, lump, or fatigue that your mind quickly connects to cancer. • Dates and anniversaries: the day you were diagnosed, finished treatment, or got difficult news. • Other people’s stories: a friend’s recurrence, a celebrity’s diagnosis, or a post in an online group. • Media and reminders: news coverage, October’s sea of pink, or walking past the hospital. • Transitions: finishing active treatment, when appointments space out and the “safety net” feels thinner. For people living with MBC, triggers often include scan cycles, rising tumor markers, a new symptom, or talk of changing treatment. Research also shows that people with more severe physical symptoms tend to report stronger fear of progression, which is one more reason good symptom management matters. Something to try: For two weeks, jot down when the fear spikes and what was happening right before. Patterns often appear quickly. Those patterns are useful to share with your care team or a counselor. Coping Strategies Backed By Research The goal isn’t to never feel afraid. It’s to keep fear from running your life. These approaches have been tested in clinical studies. Cognitive behavioral therapy (CBT) CBT helps you notice anxious thought patterns, like jumping from “my back hurts” to “the cancer has spread,” and respond to them in a more balanced way. A review of 17 randomized trials found that CBT-based programs appear to reduce fear of recurrence in people who have been diagnosed with breast cancer and who have finished active treatment. ConquerFear and similar programs ConquerFear is a structured program built specifically for fear of recurrence. It teaches skills like shifting attention away from worry, loosening the grip of “worrying keeps me safe” beliefs, mindfulness, sensible approaches to self-checking, and setting goals based on what matters to you. In a randomized trial, 222 people with a history of breast cancer, colorectal cancer, and melanoma, who completed five sessions had greater drops in fear than those who received relaxation training, with benefits lasting at least six months. An online group version for breast cancer survivors has also shown lasting benefits. Mindfulness Mindfulness means paying attention to the present moment without judging it. Instead of arguing with a scary thought, you notice it and let it pass. In another randomized trial focusing on those diagnosed with breast cancer found that six-week mindfulness-based stress reduction program reduced fear of recurrence, stress, and anxiety. National guidelines from ASCO and the Society for Integrative Oncology also recommend mindfulness-based approaches for anxiety and depression in people with cancer. Support designed for metastatic disease Most fear-of-recurrence programs were built for people with an early-stage cancer diagnosis, and researchers have found that people living with MBC need something different: strategies for living well with uncertainty, not just reassurance. Two examples: • CALM (Managing Cancer and Living Meaningfully): a short therapy, usually three to six sessions, for people with advanced cancer. In a trial of 305 people, CALM reduced depression symptoms and helped people prepare for the future compared with usual care. • Online self-guided programs: early studies of a web-based program for women with MBC showed small improvements in fear of progression. Larger trials are underway. Everyday tools that support the bigger picture • Make a scan plan. Ask how and when you’ll get results, and plan something steadying for the waiting days. • Agree on a symptom rule. Ask your team which symptoms need a call, and how long to watch others. This turns endless worrying into a clear next step. • Move your body. Structured physical activity is among the approaches ASCO recommends for anxiety and depression after cancer. • Limit the doom-scroll. It’s okay to step back from groups or news that leave you more frightened. • Name it out loud. Telling someone, “I'm scared about my scan” often takes some of the fear’s power away. The Patient Perspective: What This Fear Feels Like From The Inside Research gives us numbers. Patients give us the meaning behind them. Across studies and cancer communities, a few themes come up again and again. “Everyone thinks I’m done. I don't feel done.” For many people diagnosed with early-stage breast cancer, the end of treatment is supposed to feel like a finish line. Instead, it can feel like losing the team that was watching over you. Friends and family celebrate, while the “survivor” quietly wonders whether every ache means something. “I can't plan too far ahead.” Fear can make it hard to book a trip, change jobs, or picture next year. Researchers note that fear of recurrence is linked to difficulty planning for the future, and to both avoiding checkups and over-checking. “My fear isn’t if. It's when and how fast.” People living with MBC often describe a different kind of fear. It may center on the next scan, on how many treatment options remain, or on what progression will mean for their family and daily life. In one study, people living with MBC said clearly that they wanted tools for living well with a cancer that will likely progress, not advice written for people hoping it never returns. “I feel that others want me to just stay positive.” Some people feel pressure to stay positive at all times or that their fear is not valid when they should be grateful. Fear isn’t a contest, and it isn’t a failure of hope. “It got easier when I talked about it.” Many people describe relief once they named their fear with a counselor, a support group, or their oncology team, and realized how common it is. If any of these sound familiar, please hear this: your feelings make sense, and support is available. When To Ask For More Support It may be time to reach out if fear: • Takes up a large part of most days • Keeps you from sleeping, working, or enjoying things you used to • Leads you to skip appointments, or to check your body constantly • Comes with ongoing sadness, hopelessness, or panic ASCO recommends that everyone with cancer be checked for anxiety and depression regularly throughout their care, and that psychological therapies like CBT be offered as a first step. You can ask for that support. You don’t need to wait for someone to offer it. If you ever have thoughts of harming yourself, call or text 988 (the Suicide and Crisis Lifeline in the U.S.) or seek emergency care right away. Questions To Bring To Your Care Team 1. Is what I’m feeling a common reaction at this stage of my care? 2. Which symptoms should I call you about, and which can I watch for a while? 3. How and when will I get my scan or test results? 4. Can you refer me to a counselor, psychologist, or social worker who works with people with cancer? 5. Are there programs, support groups, or online tools for fear of recurrence or fear of progression that you recommend? 6. For MBC: can we talk about what to expect, at the level of detail I’m comfortable with? Fear may always be part of the story. But it doesn’t have to write the whole story. With the right tools and support, many people find they can carry it more lightly and make room again for the life they want to live. This article is for educational purposes only and does not replace advice from your healthcare team. Research reviewed 2026. References 1. Luigjes-Huizer YL, Tauber NM, Humphris G, et al. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psycho-Oncology. 2022;31(6):879-892. doi:10.1002/pon.5921. Link 2. Park SY, Lim JW. Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature. BMC Cancer. 2022. doi:10.1186/s12885-021-08909-y. Link 3. Butow PN, Turner J, Gilchrist J, et al. Randomized trial of ConquerFear: a novel, theoretically based psychosocial intervention for fear of cancer recurrence. Journal of Clinical Oncology. 2017;35(36):4066-4077. doi:10.1200/JCO.2017.73.1257. Link 4. ConquerFear-Group: a randomized controlled trial of an online-delivered group-based psychological intervention for fear of cancer recurrence in breast cancer survivors. Psycho-Oncology. doi:10.1002/pon.6193. Link 5. Lengacher CA, Shelton MM, Reich RR, et al. Mindfulness based stress reduction (MBSR(BC)) in breast cancer: evaluating fear of recurrence (FOR) as a mediator of psychological and physical symptoms in a randomized control trial (RCT). Journal of Behavioral Medicine. 2014;37:185-195. doi:10.1007/s10865-012-9473-6. Link 6. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psycho-Oncology. 2009;18:1261-1272. 7. Carlson LE, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. Journal of Clinical Oncology. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857. Link 8. Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. Journal of Clinical Oncology. 2023. doi:10.1200/JCO.23.00293. Link 9. Rodin G, Lo C, Rydall A, et al. Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. Journal of Clinical Oncology. 2018;36(23):2422-2432. doi:10.1200/JCO.2017.77.1097. Link 10. Feasibility, acceptability, and preliminary efficacy of a self-directed online psychosocial intervention for women with metastatic breast cancer: Finding My Way-Advanced (pilot randomized controlled trial). Link 11. Finding My Way-Advanced: a pilot evaluation of a self-directed online psychosocial intervention in improving fear of cancer progression, distress and QOL in metastatic breast cancer. Oral presentation, Cancer Survivorship Conference 2023. Link 12. Tsai JJ, Wu CJ, Hu HF, Wang YJ. Symptom severity subgroups and individual symptom-associated risk for fear of progression in metastatic breast cancer. Oncology Nursing Forum. 2026;53(3). doi:10.1188/26.ONF.e26535304. Link 13. Psychological intervention reduces cancer survivors' fear of recurrence. Healio. June 2017 (news report of ConquerFear investigators' 2017 ASCO presentation; secondary source). Link Read More: When Waiting for Test Results Breaks Your Trust in Good News The Transformative Power of Art Therapy in Cancer Survivorship 20 Sleep Hacks For A Better Night's Rest Breast Cancer and Mental Health: Recognizing and Addressing Depression and Anxiety On the Podcast: Breast Cancer Conversations Episode 310. Surviving Cancer Is Only the Beginning: How to Process What Comes After Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • GLP-1 Medications and Breast Cancer: What the Research Says So Far

    A clear, balanced look at a fast-moving area of research, and what it means for people living with and beyond breast cancer. By Laura Carfang, Ed.D. EDUCATION | NUTRITION & DIET You’ve probably heard the names: Ozempic, Wegovy, Mounjaro, Zepbound. These medications are everywhere right now, in the news, on social media, and in conversations with friends. In our breast cancer community, the questions come up often. Is it safe for me be on a GLP-1? Could it help lower my risk of the cancer coming back? Can I take it while I’m on treatment? These are smart questions, and they deserve honest answers. The short version: the research is promising in places, early in others, and not yet settled. Here’s what we know so far. Key Takeaways GLP-1 medications such as semaglutide and tirzepatide were developed for diabetes and are now also used for weight management. A review of 52 randomized trials found no increase in breast cancer risk with GLP-1 medications. A large 2026 study linked GLP-1 use to lower recurrence and death in breast cancer patients with obesity or diabetes, but it was observational and can’t prove cause and effect. People with a history of breast cancer were excluded from the main GLP-1 trials, and breast cancer–specific trials are just beginning. GLP-1s can affect how oral medications are absorbed and can add to treatment side effects, so decisions should involve your oncology team. First, what are GLP-1 medications? GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally makes after you eat. It tells your body to release insulin, slows how quickly your stomach empties, and helps you feel full. GLP-1 medications copy or boost this hormone, and their effects last much longer. They were first developed for type 2 diabetes. Some are now also approved for weight management and for lowering heart risk in certain people. Common examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Tirzepatide acts on GLP-1 and a second hormone, GIP. We’re naming them here only to help you recognize them, not to recommend any brand. Why metabolic health matters in breast cancer “Metabolic health” describes how well your body manages energy: blood sugar, insulin, body fat, cholesterol, and blood pressure. Researchers have long studied how it connects to breast cancer. Here’s what the evidence shows: • Weight and outcomes are linked. Studies have associated obesity with a higher risk of breast cancer recurrence and death. The link appears strongest in postmenopausal women and in hormone receptor-positive breast cancer. • Fat tissue makes estrogen. After menopause, body fat becomes a main source of estrogen, which can fuel hormone receptor-positive breast cancer. • Insulin may play a role. Higher insulin levels have been tied to higher breast cancer risk and to worse outcomes in some studies, even in women without diabetes. • Inflammation adds to the picture. Excess body fat is associated with ongoing, low-level inflammation that researchers believe may affect cancer growth. Treatment itself can make this harder. Many people gain weight during chemotherapy, steroid use, or years of endocrine (hormone) therapy, and lose muscle along the way. That’s exactly why GLP-1 medications have caught researchers’ attention. The question is whether they help people with breast cancer beyond managing weight and blood sugar. One important note: weight is never a measure of your worth, and no one causes their own cancer. This is about understanding biology, not assigning blame. What the research says right now Do GLP-1 medications raise breast cancer risk? Current evidence says no. A review of 52 randomized trials, covering more than 48,000 people on GLP-1 medications and nearly 41,000 who weren’t, found no increase in breast cancer or in benign breast lumps. These trials were in people with diabetes or excess weight, not in breast cancer survivors specifically. Could they lower the risk of recurrence? This is where the headlines come from, and where it’s important to slow down. In May 2026, a large study in JAMA Network Open looked at health records from more than 841,000 patients with breast cancer. Among patients with obesity or type 2 diabetes, those who used GLP-1 medications had lower rates of death and recurrence over 10 years than similar patients who didn’t. That sounds dramatic, and it may turn out to be meaningful. But there are real limits: • It’s an observational study. It looked back at records. It didn’t randomly assign people to a medication, so it can show a link but can’t prove cause and effect. • Other differences may explain it. People who get these medications may have better access to care, or other health differences that affect outcomes. • Experts raised concerns. Some independent researchers questioned the study’s methods and urged caution in drawing conclusions about breast cancer specifically. • Heart health may be part of the story. Many women treated for breast cancer ultimately face heart disease, and GLP-1s are known to lower heart risk. That may explain some of the survival difference, but not necessarily the recurrence finding. The study’s own authors said clinical trials are needed before these medications can guide cancer treatment decisions. What studies are underway? Randomized trials designed specifically for breast cancer are just getting started. Examples include: • A trial testing tirzepatide alongside standard hormone therapy in people with overweight or obesity and high-risk, hormone receptor-positive early breast cancer. • A study of tirzepatide in women who are postmenopausal and have been diagnosed with HR+ breast cancer of hormone receptor-positive breast cancer with obesity, looking at weight, body composition, and overall health. • A Mayo Clinic trial testing whether semaglutide plus lifestyle support improves heart and blood vessel health in survivors taking aromatase inhibitors. These trials will take years. Until then, GLP-1 medications are not a breast cancer treatment, and they’re not a substitute for proven therapies. Risks and considerations A history of breast cancer doesn’t automatically rule out a GLP-1 medication. But it does mean the decision should be made together with your oncology team, not just the prescriber of the GLP-1. Here’s what to weigh. People with breast cancer weren’t in the main trials. The large studies that led to FDA approval of semaglutide and tirzepatide for weight loss excluded people with a history of breast cancer. Early studies in survivors have found weight loss and side effects similar to people without cancer, but the data are still limited. Effects on oral cancer medications. GLP-1s slow how quickly the stomach empties. That can change the timing of when pills are absorbed. Experts say this deserves a conversation if you take oral cancer drugs, such as anti-estrogen pills or capecitabine (Xeloda). Severe vomiting can also mean losing a dose entirely. Overlapping side effects during treatment. Nausea, vomiting, constipation, and reduced appetite are common with GLP-1s, and with chemotherapy. Taking both can make it hard to tell what’s causing what, and harder to eat enough. Many teams pause GLP-1s during intense treatment, but this is decided case by case. Muscle and bone. A meaningful share of the weight lost on GLP-1s can come from muscle, not just fat. Cancer treatment can already reduce muscle and bone strength. Adequate protein, strength training, and nutrition support matter. Thyroid history. People with a personal or family history of certain thyroid cancers (medullary thyroid cancer) or a related genetic syndrome are advised not to use these medications. Cost and access. Coverage varies widely, and supply and pricing have shifted. Compounded or online versions aren’t held to the same standards as FDA-approved products, so talk with your team before going that route. Questions to bring to your care team 1. Given my diagnosis and treatment, is a GLP-1 medication something to consider for me? 2. Could it interact with any of my cancer medications, especially pills I take by mouth? 3. Should I pause it during chemotherapy, surgery, or other treatment? 4. How will we protect my muscle and bone health if I lose weight? 5. Who should manage this medication, and how will they coordinate with my oncologist? 6. Are there clinical trials studying GLP-1 medications in people like me? 7. What other ways can we support my metabolic health, like nutrition, physical activity, or sleep? The bottom line GLP-1 medications are one of the most talked-about developments in medicine, and their connection to breast cancer is worth watching closely. Early data are encouraging, and safety data so far are reassuring. But we don’t yet have the randomized trials needed to know whether these medications change breast cancer outcomes. For now, the best approach is an informed, individual conversation with your care team, one that weighs your health goals, your treatment, and the full picture of benefits and risks. Note: This article offers general information and does not replace professional medical advice. Make sure to discuss your options with your healthcare provider. Read More: The Role of Nutrition in Breast Cancer Recovery: Optimizing Your Diet for Healing Understanding and Managing GI Issues Caused by Breast Cancer Treatment GLP-1 Medications and Breast Cancer: What the Latest Research Really Means On the Podcast: Breast Cancer Conversations Episode 291. Breast Cancer Survivorship: Exercise, Nutrition, Sleep, and Support Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • When Your Symptoms Don’t Show Up on a Test

    There is a stretch in which you feel unwell and every test says you are fine. It has a name, and knowing it changes the conversation you can have with your care team. By Laura Carfang, Ed.D. EDUCATION | SURGERY When Your Symptoms Don’t Show Up on a Test You know something has changed. The fatigue is not the ordinary kind. There is a heaviness, or a tightness, or a headache that keeps returning. You bring it up, and the workup comes back clean. So you are sent to someone else. Then someone else. Each visit begins again from the top, and each one ends with a version of the same sentence: your labs look good. At SurvivingBreastCancer.org we hear this constantly, and the detail that comes up again and again is not pain. It is the feeling of not being believed — or, more precisely, of not being measurable. Nobody has told you that you are imagining it. They have simply run out of tests to run. That stretch has a name. It is not a diagnosis, and naming it does not explain what is happening in any particular body. But it does something useful: it gives you language for a real clinical situation, instead of leaving you to wonder whether the problem is you. Listen Now The prodromal phase On a recent episode of Breast Cancer Conversations, Dr. Robert Whitfield, a plastic and reconstructive surgeon in Austin who spent fifteen years in cancer reconstruction, described it in a way that landed. He was talking about how obvious a problem is once it declares itself. If someone arrives with a red, swollen, painful chest and a fever, nobody is confused. Everyone knows what that is and what to do about it. But before that, he said, there is a prodromal phase. You are getting sick, but you are not sick yet. The word comes from medicine’s oldest vocabulary. A prodrome is the early stage of an illness, the part that precedes the signs anyone can point to. The body has begun responding to something. The response has not yet crossed the threshold where our instruments can see it. Medicine is built around thresholds. A fever is a number. An elevated marker is a number. Redness and swelling are visible. These are good tools, and they work well for the problems they were designed to catch. What they are not built for is the interval before the number moves. Why the standard workup comes back clean When you describe vague, systemic symptoms, a clinician usually reaches for the same handful of tests. Dr. Whitfield named them directly, and was blunt about their limits. C-reactive protein (CRP) rises with significant inflammation. Sed rate (erythrocyte sedimentation rate) is an older, broader inflammation marker. IL-6 is a signaling molecule involved in inflammatory response. All three are useful. All three are also blunt instruments, and in his experience they typically read normal in exactly the situation being described. His phrasing was that these tests are antiquated, not useless, but not designed for this question. There is no single blood panel you can order that settles it. A normal result means the test did not detect the thing it measures. It does not mean nothing is happening. Those are different statements, and in a fifteen-minute appointment they collapse into one. One place this shows up: implants Before going further, I want to if you have implants and you feel well, this is not a warning about your body. Most people with implant reconstruction respond incredible well fine. This section is here because implants are a clear, well-studied example of the gap described above and not because having them means something is wrong. What is firmly established is capsular contracture. Your body forms a capsule of scar tissue around any implant; that is normal and expected. In some people that capsule thickens and tightens, and the breast becomes firm, higher-riding, misshapen or painful. It is graded on a four-point scale, it is recognized by every plastic surgeon, and there are established ways to manage it. If this is what you have, you are on well-mapped ground. There is also BIA-ALCL — breast implant-associated anaplastic large cell lymphoma. It is rare, it is recognized by the FDA, and it has been linked primarily to textured implants. The usual presenting sign is late swelling or fluid collection around the implant, often years after surgery. It is worth knowing the name so you can ask about it directly. And then there is the territory that is still being worked out. Dr. Whitfield’s practice began sending capsule tissue for PCR analysis rather than relying only on traditional culture, on the reasoning that conventional culture requires bacteria to be alive and present in enough quantity to grow, while PCR detects genetic material either way. His published series found bacterial contamination in 29% of samples. That figure needs its denominator, and he supplied it himself in the interview. It is 29% of the tissue samples from his own patients — people who had already sought him out with problems and had elected to have implants removed. It is not 29% of women with implants. Asked directly whether it could be generalized, he said no, and added that nobody has the population number. He was equally plain that a positive finding does not establish cause. His words were that we do not know how much it contributes in any individual person. The honest summary is that this is an area where the science is still catching up with what patients report. Dr. Whitfield said as much, and pointed to a 2025 study from Denmark examining immune cell activity in capsule tissue as the kind of work that will eventually produce better answers. What you can actually do Write it down as it happens. Date, symptom, how long, what you were doing, how bad out of ten. A pattern across six weeks is evidence. Give it a shape before you walk in. One sentence: what changed, when it started, and what you want from this visit. Clinicians are working inside short appointments. A clear opening sentence is not pushiness; it is the most useful gift you can hand them. Ask the question underneath the answer. When a test comes back normal, a fair follow-up is: what would this test have caught, and what would it miss? It is a real question with a real answer, and it moves the conversation forward instead of ending it. Keep the whole team informed. If you have implants, make sure your oncologist, your primary care physician and your plastic surgeon are all aware of what you are experiencing. A symptom that looks unremarkable to one of them may matter to another. A second opinion is a normal thing to seek. If your workup is complete, your symptoms persist, and the conversation has stalled, asking someone else to look is reasonable medical practice. It is not disloyalty to your team. And if you are weighing removal: that is a surgical decision, with its own risks and its own recovery, to be made with your own team. There is no single correct answer, and anyone who tells you otherwise — in either direction — is overstating what is known. Note: This article offers general information and does not replace professional medical advice. Make sure to discuss your options with your healthcare provider. Read More: Exploring Breast Reconstruction Surgery: Pros and Cons Breast Reconstruction Surgery: Options, Considerations, and Recovery Going Flat and Explant Surgery On the Podcast: Breast Cancer Conversations Episode 318. When Breast Reconstruction Causes Problems with Dr. Whitfield Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Supportive Care, Palliative Care, and Hospice: Understanding the Differences

    Three kinds of care that are often confused, and why understanding them early can change how you live with breast cancer. By Laura Carfang, Ed.D. EDUCATION | METASTATIC BREAST CANCER Few words in cancer care carry as much weight, or as much misunderstanding, as “palliative“ and “hospice.” For many people, hearing either one feels like hearing that time is running out. But that’s not what these words mean. Supportive care and palliative care are about one thing: helping you feel as well as possible, for as long as possible, at any stage of breast cancer. Hospice is a specific kind of palliative care for the final months of life. Knowing the difference matters. When people avoid palliative care because they think it means giving up, they can miss out on support that research shows improves quality of life, and sometimes even length of life. Key Takeaways Supportive care helps you cope with cancer and its treatment from the day you’re diagnosed. Palliative care is specialized care for symptoms and stress, and you can receive it at the same time as active cancer treatment. Hospice is comfort-focused care for the final phase of life, generally when life expectancy is six months or less. ASCO recommends early palliative care for people with advanced cancer, and research shows it improves quality of life. Choosing palliative care doesn’t mean giving up, and you can leave hospice if your plans change. What each type of care means Supportive care Supportive care is the broadest term. It includes anything that helps you cope with cancer and its treatment, beyond the treatment itself. Think anti-nausea medicine, physical therapy, nutrition counseling, mental health support, lymphedema care, fertility counseling, financial navigation, and support groups. Supportive care can start the day you’re diagnosed and continue through survivorship. Your oncology team, nurses, social workers, and many other specialists provide it. Palliative care Palliative care is specialized medical care focused on relieving symptoms and stress from a serious illness. Its goal is to improve quality of life for both the patient and the family. A palliative care team usually includes doctors, nurses, social workers, and sometimes chaplains or nutritionists. They help with: • Pain, fatigue, nausea, shortness of breath, and other symptoms • Anxiety, depression, and emotional distress • Understanding your illness and your options • Clarifying your goals and values, and making decisions that fit them • Coordinating care across your medical team • Supporting caregivers and family Most importantly, palliative care can happen at the same time as active cancer treatment, including chemotherapy, targeted therapy, surgery, or clinical trials. You don’t have to stop anything to receive it. Hospice care Hospice is for the last phase of life, when the focus shifts from treating the cancer to comfort and quality of life. Hospice teams provide nursing, medical equipment, medications for comfort, counseling, spiritual care, and support for family, including grief support. Most hospice care happens at home. In the U.S., the Medicare hospice benefit requires that a doctor certify a life expectancy of six months or less if the illness follows its usual course. The person also chooses comfort-focused care instead of treatment aimed at curing or controlling the cancer. Two things people often don’t know: • Six months is not a countdown. People can stay on hospice longer if they continue to qualify. • Hospice isn’t permanent. You can leave hospice to pursue treatment, such as a new clinical trial, and return later if needed. One of the biggest misconceptions in cancer care is that palliative care is only for patients nearing the end of life. In reality, palliative care can help people at any stage of a serious illness by improving quality of life, managing symptoms, and providing emotional, practical, and even financial support. Click the video to watch this SBC panel where 5 women living with metastatic breast cancer discuss their experiences and demystify what palliative care actually is. Why earlier is better Recent research continues to show that palliative care helps most when it starts early, alongside cancer treatment, rather than when treatment options run out. A new study in breast cancer. In June 2026, researchers in New Delhi, India, presented a randomized trial of 110 people newly diagnosed with breast cancer, most with advanced disease. Half were referred to palliative care within a week of diagnosis and seen at least monthly, alongside their cancer treatment. The other half received palliative care only when they asked for it or when treatment stopped working. After three months, the early palliative care group: More often reported a meaningful improvement in quality of life (about 70% versus 54%) Had a larger drop in symptom distress Saw their social functioning improve, while it declined in the comparison group This was a small, single-center study presented at a medical meeting and not yet published in a journal, and it didn’t report on survival. But it is one of the few randomized trials of early palliative care focused specifically on breast cancer. Palliative care by video works, too. A large 2024 trial at 22 U.S. cancer centers enrolled 1,250 people with advanced lung cancer. Everyone received early palliative care, either in person or mostly by video. Quality of life was equivalent in both groups. That matters for anyone who lives far from a cancer center or finds travel exhausting: telehealth can make early palliative care easier to get. One trade-off: family caregivers were less likely to join video visits. What the guidelines say In its 2024 guideline update, the American Society of Clinical Oncology (ASCO) reviewed 52 randomized trials and recommends that people with advanced cancer be referred to a specialized palliative care team early in their illness, alongside active treatment. The recommendation is strongest for people whose symptoms aren’t well controlled or who have concerns about quality of life. The guideline also says caregivers, including family, chosen family, and friends, can be referred for support. Earlier ASCO guidance set a target of referral within eight weeks of an advanced cancer diagnosis. The 2024 update dropped the fixed deadline, partly because there aren’t enough palliative care specialists to meet it everywhere. Instead, it asks care teams to treat “early” as meaning before cancer treatment stops, not after. If your team hasn’t raised it, you can. What this means for breast cancer If you have early-stage breast cancer, supportive care is for you, from managing chemo side effects to counseling, exercise programs, and survivorship clinics. If symptoms are hard to control, you can ask about palliative care, too. If you’re living with metastatic breast cancer, palliative care can be part of your care team from the start, often for years, alongside your treatment. It’s not a signal that treatment has stopped. It’s an extra layer of support. Hospice becomes an option when treatment is no longer helping or its burdens outweigh its benefits, and comfort becomes the main goal. Myths and facts Myth: Palliative care means giving up. Fact: Palliative care is added to your treatment, not swapped for it. Its purpose is to help you feel better and live better while you continue the treatments you choose. Myth: Palliative care is only for the last days of life. Fact: Palliative care can begin at diagnosis and continue for years, and guidelines recommend starting early for advanced cancer. Myth: Asking about palliative care will upset my oncologist. Fact: Major oncology guidelines recommend it. Asking shows that you’re an engaged member of your own care team. Myth: Hospice means you’ll die sooner. Fact: Hospice doesn’t speed up death. Its focus is comfort, symptom relief, and support for you and your family during the time you have. Myth: Once you start hospice, you can’t change your mind. Fact: You can leave hospice at any time, for example to try a new treatment, and come back later if needed. Myth: Hospice is a place. Fact: Hospice is a type of care, and most of it happens wherever you call home. Myth: Choosing comfort means I’ve lost hope. Fact: Hope can change shape without disappearing. People often describe hoping for good days, meaningful time with loved ones, less pain, and peace. Those hopes matter. Stigma also falls unevenly. ASCO’s 2024 guideline notes that racial and ethnic disparities, income, where people live, and insurance coverage all affect access to good cancer care. Everyone deserves to understand and use these services, and to have their cultural and spiritual values respected along the way. How to ask for this care You don’t need to wait for someone to bring it up. You can start the conversation with a simple sentence: “I’d like to learn more about supportive care and palliative care. Can you refer me?” Many cancer centers have palliative care clinics. If yours doesn’t, ask your team about telehealth options or community programs. Palliative care is typically covered by Medicare, Medicaid, and most private insurance like other medical specialties, though copays may apply. Questions to bring to your care team 1. What supportive care services are available to me right now? 2. Would a palliative care referral help with my symptoms or stress? 3. Can I see a palliative care team while I continue my current treatment? 4. Are there services to support my caregiver or family? 5. How will we know if, and when, hospice might be the right choice? 6. What would hospice look like for me, and could I stop it if my plans change? 7. Who can help me document my wishes, like an advance directive or health care proxy? The right support at the right time can make the hardest parts of breast cancer a little lighter. Knowing these options exist, and that asking for them is a sign of strength, is a powerful first step. This article is for educational purposes only and is not medical, legal, or insurance advice. Hospice eligibility rules described here refer to the U.S. Medicare benefit; other insurers may differ. Research reviewed November 8, 2026. Read More: Understanding Advanced Treatment Options for Metastatic Breast Cancer Questions to Ask Your Doctor After a Breast Cancer Diagnosis Why a Second Opinion Matters for Breast Cancer On the Podcast: Breast Cancer Conversations Episode 307: What Long-Term Living with Metastatic Breast Cancer Really Looks Like Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • 4 Years On

    By Jill Rackham COMMUNITY | POETRY Time has moved on and now 4 years have past, since my breast cancer diagnosis hit me full on like a blast. I can hardly remember life before this day. This cancer world still has so much to say. Oncology appointments and scans continue so I find myself being brave. Remaining free of cancer is something I will forever crave. Living with this risk leads to unwanted thoughts of cancer. Mental Chatter is forever talking and searching for an answer. My treatment forced me into the menopause early which is no easy task. The effects of this on my mind and body definitely still feel vast. However, other health findings have also made this a difficult year. New conditions to manage bring about more stress adding to my fear. My family and friends are amazing but life can feel such a lonely place. This renewed normal I have can give me anxiety in all I seem to face. I long for a time of fewer medical appointments, a time when I can feel free. But I stand by my mantra of 'onwards and upwards' - this has to be. I know aging is a gift so I will embrace everything that comes along. I will hold on to all the positives in my life hopefully forever feeling strong. Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Dense Breasts: Screening and Surveillance After Diagnosis

    Here’s what to know about breast density, screening options, and questions to discuss with your healthcare team. SurvivingBreastCancer.org Editorial EDUCATION | BREAST DENSITY Key Takeaways Dense breasts are common and can raise the risk of developing breast cancer. Dense tissue can hide tumors on a mammogram. Mammograms remain a useful screening tool for everyone including for people with dense breasts. If you have dense breast tissue, additional screening may help depending on your personal risk factors. Your healthcare provider can help you build an appropriate screening plan. Dense breast tissue on your mammogram report may raise questions about cancer risk and whether you need additional screening. Approximately half of women ages 40 and older who receive mammograms have dense breasts. Breast density is not a cancer diagnosis, but it can increase breast cancer risk and make cancer harder to detect on a mammogram. What Are Dense Breasts? Breasts consist of three tissue types: fibrous tissue, glandular tissue, and fat. Fibrous tissue holds everything in place, glandular tissue produces and transports milk, and fatty tissue fills the surrounding space. Breast density describes the proportion of fibrous and glandular tissue relative to fatty tissue. Radiologists classify breast tissue into four distinct categories on a mammogram: Category A: Almost entirely fatty tissue. Category B: Scattered areas of fibroglandular density. Category C: Heterogeneously dense tissue, which can obscure small masses. Category D: Extremely dense tissue, which lowers mammogram sensitivity. Categories C and D fall under the umbrella of “dense breasts.” Breast density relates entirely to internal tissue structure, not breast size, firmness, or external appearance. Factors such as genetics, younger age, lower body mass index, and menopausal hormone therapy often contribute to higher tissue density. Why Breast Density Matters for Screening Dense breast tissue affects breast cancer detection and risk. On a standard 2D mammogram, fatty tissue appears dark, while fibrous tissue, glandular tissue, and potential tumors appear white. That overlap can make cancer harder to spot, a challenge called the masking effect. Higher breast density also increases the risk of developing breast cancer, although researchers do not fully understand why. Breast density is one factor in assessing overall risk. For people who have already received a breast cancer diagnosis, follow-up imaging recommendations may differ from routine screening guidelines. Your care team will consider your diagnosis, treatment history, breast surgery, breast density, and other risk factors when developing a personalized surveillance plan to monitor for recurrence or a new breast cancer. How Can You Learn Your Breast Density? As of September 10, 2024, mammography facilities across the United States are required by federal law to notify patients about their breast density as part of their mammogram results. This requirement, established by the FDA under the Mammography Quality Standards Act (MQSA), helps patients better understand their breast density and have informed conversations with their healthcare providers about breast cancer risk and screening options. Your report should indicate whether your breasts fall into a dense or nondense category. A dense-breast notification doesn’t mean the radiologist found cancer or another abnormality. It alerts you that density may affect how the radiologist interprets your mammogram and your overall risk. Review both the density information and the rest of your mammogram results. Contact your healthcare provider if the language feels unclear or if the report recommends follow-up care. Do You Still Need Mammograms? Yes. Mammograms remain the primary breast cancer screening test, even for people with dense breasts. They can detect many cancers before a lump or other symptom appears. Breast cancer screening guidelines vary among leading medical organizations. The U.S. Preventive Services Task Force (USPSTF) recommends mammograms every two years for women ages 40–74. However, the American College of Radiology (ACR) recommends annual mammograms beginning at age 40, while the American Cancer Society (ACS) offers the option to begin annual screening at age 40, recommends annual screening from ages 45–54, and allows women 55 and older to continue annually or transition to every two years. Your screening schedule should reflect your individual risk factors, including breast density, family history, genetic predisposition, and personal medical history. Talk with your healthcare provider about whether annual screening or additional imaging may be appropriate for you. Never delay care while waiting for your next routine mammogram if you notice a lump, nipple discharge, skin dimpling, breast swelling, or another change. Report new symptoms promptly, regardless of your most recent results. Exploring Supplemental Screening Options Mammograms remain a key tool for detecting breast cancer early. For people with dense breast tissue, additional imaging such as ultrasound and MRI may find cancers that mammography misses, but it can also produce false positives, leading to extra testing or biopsies that don’t find cancer. Supplemental screening decisions should reflect your overall risk and preferences. Imaging options to discuss with your medical team include: 3D Mammography: Also called digital breast tomosynthesis, it takes X-ray images from multiple angles to show breast tissue in thin slices. It is a mammography option, not a separate supplemental test. Breast Ultrasound: Uses sound waves to examine tissue and distinguish fluid-filled cysts from solid masses. It may detect cancers that mammograms miss. Breast MRI: Uses magnetic fields to create detailed images. It can detect cancers that mammograms miss and is often recommended alongside mammography for people at high risk. Recommendations for additional screening vary among medical organizations. The U.S. Preventive Services Task Force (USPSTF) concludes that more research is needed to determine whether the benefits of supplemental ultrasound or MRI outweigh potential harms for people with dense breasts who have a negative mammogram. Meanwhile, the American College of Radiology (ACR) recommends considering additional imaging based on breast density and overall breast cancer risk. Having dense breasts does not automatically mean you need additional screening, but it is an important factor to discuss with your healthcare provider when developing a personalized breast cancer screening plan. Take an Active Role in Your Breast Health A dense-breast notification offers useful information, not a diagnosis. Keep your mammography appointments, learn your personal risk factors, and discuss your screening plan with a qualified healthcare professional. Knowing your breast density gives you another tool for advocating for your health. Use that knowledge to ask questions, understand your options, and work with your care team to choose an appropriate screening approach. Questions to Ask at Your Breast Screening Appointment What is my breast density, and how does it affect my mammogram? What is my overall breast cancer risk? How often should I have mammograms, and is 3D mammography appropriate for me? Should I consider additional imaging, such as ultrasound or MRI? What are the potential benefits, risks, and costs? If I have had breast cancer, how does my surveillance plan differ from routine screening? When will I receive my results, and what happens if I need follow-up testing? Count on Us for Education and Support Whether you’re newly diagnosed with breast cancer, navigating survivorship, or supporting someone you love, SurvivingBreastCancer.org helps bridge the gap between medical care and everyday life. We believe access to reliable, evidence-informed education is essential to cancer care. Whether you’re learning about screening, navigating a new diagnosis, or managing your health during and beyond treatment, we’re here to help you make sense of complex medical information. We offer programs, including virtual support groups, along with trusted educational resources and podcasts featuring professionals, advocates, and caregivers. Your support helps SurvivingBreastCancer.org continue providing knowledge, connection, and community to those impacted by breast cancer, every day, all year long. Note: This article is designed to provide general information and is not meant to replace professional medical advice. Always discuss your options with your healthcare provider. Read More: What are Dense Breasts? How to Improve Cancer Screening for People with Dense Breasts Understanding Your Pathology Report: A Comprehensive Step-By-Step Guide AI Advances in Breast Cancer Detection and Treatment On the Podcast: Breast Cancer Conversations Episode 301. Why Are Women Still Waiting Months for Breast Cancer Answers? Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Your Body Sends You Signals. Learn to Listen.

    By Rosana Fernández COMMUNITY | BREAST CANCER STORIES I’m 57 years old and I live in St. Augustine, Florida. And I feel blessed with every day of life I’ve been given. I live with psoriatic arthritis, fibromyalgia, asthma, migraines, depression, anxiety, post-traumatic stress disorder, kidney disease, and a neurogenic bladder. For more than 20 years, I lived with gastroparesis. That chapter came to an end on November 4, 2025, when I underwent a total gastrectomy and had my stomach removed. I have also received three breast cancer diagnoses. The most recent one came in March 2026. And even with everything I’ve faced, I still feel that, overall, my health is blessed. I’ve lost count of how many surgeries I’ve had, but it’s well over twenty. Every scar is a reminder of a battle I’ve fought—and won. They remind me that my purpose in life is not yet complete. Hearing the words “You have cancer” is something no one should ever experience. The first time, it was overwhelming, especially since I was young and death felt far away. The second time, I was shocked again, but I remembered that I had already beaten it once. That memory gave me the strength to keep going. But hearing it a third time… A third diagnosis is different. There was fear. There was anger. And when I was already living with anxiety, depression, and post-traumatic stress disorder, another battle began inside my mind. One part of me fought to believe I would overcome it again, while another whispered that this time I wouldn’t. On May 13, 2026, I underwent a bilateral radical mastectomy. In a matter of hours, I went from wearing a size 38C bra to waking up completely flat. Seeing my body after surgery was heartbreaking. I cried like a little girl. But through those tears, I kept telling myself: “This was the best decision of my life.” My first two breast cancers were diagnosed as carcinoma in situ. I truly believe they were found early because I was consistent about my breast health and regular screenings. This third diagnosis developed in less than a year between mammograms. It was invasive lobular carcinoma, HER2-positive, fortunately detected at an early stage (stage 1A). Because it was found early and I underwent a bilateral radical mastectomy with lymph node removal, I did not need chemotherapy or radiation. On Wednesday, July 22, my oncologist wasn’t able to give me the medical discharge I had been hoping for. Instead, I began the next phase of my treatment: five years of hormone therapy. One pill every day. The goal is to reduce the chance that the cancer returns somewhere else in my body by lowering estrogen, a hormone that can fuel the growth of certain breast cancers. The day I took my first pill, a new countdown began. 1,825 days. 60 months. Five years. And I want to use every one of those days to help other women going through similar experiences. Since my very first diagnosis, I have shared the same message: Perform breast self-awareness. See your breast specialist. Have your mammograms when your doctor recommends them. If you’re not yet old enough for mammograms, ask your doctor whether breast ultrasound is appropriate. Every step matters. Listen to your body. It is one of God’s most incredible creations. Your body sends you signals. Learn to listen. Months before my most recent diagnosis, my body was trying to tell me something. I felt an intense itch deep inside my breast, behind my nipple. It wouldn’t go away. That was the cancer speaking. If your body tells you something isn’t right, don’t ignore it. Seek medical attention. Hopefully, it will turn out to be nothing serious. But if it is cancer, finding it early can make all the difference. Read More: Understanding Breast Cancer in Young Adults The Role of Hormones in Breast Cancer The Impact of Breast Cancer on Self-Image Ductal Carcinoma in Situ (“Stage Zero” Breast Cancer): What You Need To Know On the Podcast: Breast Cancer Conversations Episode 313. Tamoxifen Changed My Body: The Side Effects We Don't Talk About with Lindsey Campbell Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • What’s Missing in Breast Cancer Care? 5 Gaps Patients Still Face

    From emotional support and integrative oncology to metastatic breast cancer research, financial assistance, and clinical trial access, four nonprofit leaders discuss what it will take to build a more connected system of cancer care. Laura Carfang, Ed.D. Editorial EDUCATION | SURVIVORSHIP Key Takeaways Excellent medical treatment isn’t the same as comprehensive care. The needs that fall outside a clinical appointment — emotional, practical, financial — are central to the cancer experience, not extras. The problem isn’t missing resources — it’s fragmented access. Whether someone gets support too often depends on where they live, where they’re treated, and whether they know to ask. Emotional and peer support shouldn’t depend on your cancer center. Personalized, stage-specific connection reaches places clinical expertise alone can’t. Whole-person care is still priced like a luxury. When integrative and supportive services aren’t covered by insurance, access splits along financial lines — and quality of life shouldn’t. Metastatic breast cancer needs both research and dedicated support. As METAvivor’s Dr. Kelly Shanahan puts it, “I live because of research” — and living well also requires stage-specific community and navigation. The biggest opportunity is connecting what already exists. No single organization can do it all; stronger partnerships, referrals, and sustained investment in nonprofits are how the system improves. A breast cancer diagnosis sets an entire medical system into motion. There are imaging appointments, pathology reports, treatment plans, surgeries, medications, and follow-up visits. Oncologists, surgeons, nurses, and other specialists work to deliver increasingly sophisticated treatments, informed by decades of research and medical innovation. But what happens to the needs that don’t fit neatly into a medical appointment? Who helps someone navigate the emotional impact of a diagnosis? Who addresses the financial strain of traveling to treatment, the difficulty of managing persistent side effects, or the challenge of finding a support community that understands their particular experience? And who helps patients find these resources when they’re already overwhelmed by everything else? These questions reveal an important distinction: Receiving excellent medical treatment is not the same as having access to comprehensive cancer care. To explore these gaps, SurvivingBreastCancer.org brought together four nonprofit leaders for a special episode of Breast Cancer Conversations: Laura Carfang, Co-Founder and CEO of SurvivingBreastCancer.org Ellen Friebert Schupper, CEO of ABCD: After Breast Cancer Diagnosis Kelly Shanahan, MD, President of METAvivor Sue Weldon, Founder and CEO of Unite for HER Each organization serves the breast cancer community differently, from peer-to-peer emotional support and metastatic breast cancer research to integrative oncology, education, and community-based programs. Yet across these different missions, a common theme emerged: The problem isn’t simply that supportive resources don’t exist. It’s that access to those resources remains fragmented, inconsistent, and often dependent on where someone lives, receives treatment, or knows to look. Here are five gaps that deserve greater attention and what it could take to close them. Listen now on the Podcast: Breast Cancer Conversations 1. Emotional Support Shouldn’t Depend on Where You’re Treated A cancer diagnosis changes more than someone’s medical chart. It can alter relationships, employment, identity, family dynamics, and a person’s sense of security about the future. Yet access to emotional and peer support varies considerably. Some cancer centers have established support programs and patient navigators. Others have limited resources. And even when support exists, patients may not know where to find it or may need something different from what’s offered locally. For Ellen Friebert Schupper, CEO of ABCD: After Breast Cancer Diagnosis, this is precisely why personalized one-on-one peer support matters. ABCD specializes in connecting people affected by breast cancer with trained mentors who can offer one-to-one emotional support grounded in lived experience. This type of connection fills a need that clinical expertise, however valuable, cannot always address. Someone newly diagnosed may want to speak with another person who remembers the uncertainty of those first appointments. Someone experiencing difficult treatment side effects may need reassurance that their concerns deserve to be heard. A person living with metastatic breast cancer may want a peer mentor where conversations about progression, ongoing treatment, and uncertainty are understood. During the roundtable, METAvivor President Kelly Shanahan shared the organization’s origins: women living with metastatic breast cancer who found that an existing support group was not prepared to accommodate their experiences. Rather than abandon their need for community, they created their own. Their efforts eventually helped build an organization dedicated to metastatic breast cancer research, advocacy, and support. The lesson extends well beyond any one diagnosis or organization. Support must be responsive to the person seeking it and not limited by what a particular institution or organization happens to offer. This is also why partnerships matter. SurvivingBreastCancer.org offers moderated support groups for different stages and experiences including early stage breast cancer, metastatic breast cancer, and inflammatory breast cancer to name a few, while ABCD specializes in individual mentor matching. These services complement one another rather than compete. 2. Whole-Person Cancer Care Remains Out of Reach for Too Many People Cancer treatment is designed to treat the disease. But the effects of cancer and its treatment can extend into nearly every aspect of daily life. Fatigue, sleep disturbances, anxiety, pain, changes in physical functioning, and other symptoms may persist during treatment and beyond. These concerns deserve attention as part of comprehensive cancer care. Evidence-informed supportive approaches including exercise, nutrition counseling, psychosocial interventions, and selected integrative therapies can help address particular symptoms and quality-of-life concerns. The evidence and recommendations differ by intervention and symptom, making individualized guidance important. Yet access is far from universal. Sue Weldon, Founder and CEO of Unite for HER, experienced this gap firsthand following her own breast cancer diagnosis. While navigating treatment and its side effects, she sought complementary supportive services that were not readily integrated into her medical care. That experience ultimately shaped Unite for HER’s mission: expanding access to integrative therapies and supportive resources for people affected by breast and ovarian cancers. As Sue explained during the conversation, the challenge isn’t simply awareness. It’s affordability. Many supportive services are not consistently covered by insurance, leaving patients to pay out of pocket or forgo them altogether. And when families are already managing medical expenses, lost wages, transportation costs, and other financial pressures, additional wellness services may feel impossible to prioritize. This creates an inequity: people with greater financial resources may be able to access supportive care that others cannot. Whole-person care should not be a luxury reserved for those who can afford it. At SurvivingBreastCancer.org, we’re working to make whole-person support more accessible through free virtual wellness programming, including movement, mindfulness, and other evidence-informed practices designed to support physical and emotional well-being during and beyond treatment. The strongest model is one in which evidence-informed supportive care works alongside oncology treatment, helping people manage symptoms, maintain function, and improve quality of life. For healthcare systems, this raises an important question: If we recognize that quality of life matters during cancer treatment, how do we make the services that support it more consistently accessible? 3. Metastatic Breast Cancer Requires Sustained Research and Dedicated Support Scientific progress has transformed breast cancer treatment, with new therapies and increasingly personalized approaches expanding options for many patients. But metastatic breast cancer (MBC) remains an incurable disease requiring ongoing treatment and careful management. For Kelly Shanahan, this reality is both professional and deeply personal. A physician diagnosed initially with early-stage breast cancer, Kelly later developed metastatic disease. Treatment-related neuropathy affected her ability to continue practicing medicine, and she eventually found a renewed sense of purpose through advocacy and leadership at METAvivor. During the roundtable, she described the role research has played in her life with remarkable clarity: “I live because of research.” Her words underscore why continued investment in metastatic breast cancer research is essential. Research advances are not abstract scientific milestones. They can translate into additional treatment options, longer periods of disease control, and improved quality of life. But the needs of people living with metastatic breast cancer extend beyond new therapies. Patients may face treatment changes, progression, cumulative side effects, disruptions to employment, and the ongoing emotional weight of living with an incurable illness. They may also need stage-specific support that acknowledges these realities rather than minimizing or avoiding them. Kelly emphasized that metastatic breast cancer research, community, and advocacy are interconnected priorities. That perspective challenges a tendency to separate scientific progress from the daily experiences of people living with advanced disease. Better treatments matter. So does the ability to live well while receiving them. A more complete approach to metastatic breast cancer must support both goals. It must also recognize the importance of involving people living with MBC in decisions about research priorities, supportive care programs, and policies that directly affect their lives. 4. Cancer Navigation, Clinical Trials, and Specialized Care Are Still Too Difficult to Access Cancer care is becoming more sophisticated. Treatment decisions may depend on tumor subtype, biomarkers, previous therapies, genetic information, and a rapidly evolving body of clinical evidence. These advances create important opportunities. They also make it increasingly difficult for patients to navigate the system without specialized guidance. During the roundtable, Kelly described traveling hundreds of miles to see specialists with expertise in metastatic breast cancer. Her experience highlights a broader access challenge. For someone living in a rural community, obtaining a second opinion may involve long drives, time away from work, childcare arrangements, transportation expenses, and logistical obstacles. For others, the barrier may be uncertainty about which specialist to see or whether a clinical trial is available. And for people receiving treatment at community cancer centers, access to disease-specific expertise may be limited by geography and resources. Clinical trials present another significant opportunity and also another potential gap. Patients may not know when to ask about a clinical trial, how eligibility is determined, or where studies are available and discussions about trials may happen inconsistently across care settings. As the panel discussed, clinical trials should not be framed solely as a last resort. Depending on the diagnosis and circumstances, they may be relevant at different points in care. But awareness alone is not enough. People diagnosed with breast cancer and living with metastatic disease also need practical help understanding options, identifying appropriate resources, and navigating the steps required to explore participation. This is where stronger cancer navigation could make a meaningful difference. Imagine a system in which someone diagnosed with breast cancer could easily access: Clear, understandable information about their diagnosis and treatment options Guidance on obtaining an appropriate specialist consultation or second opinion Information about clinical trials and how to discuss eligibility with their care team Referrals to emotional, financial, and supportive care services Help identifying resources that match their diagnosis, location, and individual needs Some of these services exist today. The challenge is making them easier to discover, access, and coordinate. Patients should not have to become experts in navigating healthcare systems simply to receive the support they need. Improving access will require collaboration among cancer centers, community oncologists, patient organizations, researchers, and industry partners. It will also require attention to rural communities, historically underserved populations, and people who face language, transportation, financial, or digital barriers. 5. The Financial Burden of Breast Cancer Extends Far Beyond Medical Bills When we discuss the cost of cancer, attention often centers on treatment expenses, insurance coverage, and prescription medications. But the financial impact of a diagnosis reaches much further. A person receiving treatment may need to travel regularly to appointments, purchase groceries while unable to work, arrange childcare, or cover household expenses while income is reduced. For people living with metastatic breast cancer, these challenges are lifelong. The roundtable highlighted direct financial assistance as an important unmet need, alongside better navigation and access to supportive services. This is particularly significant because financial hardship can affect more than a household budget. It can influence whether someone can reliably travel to appointments, access supportive services, or manage the practical demands of treatment. Nonprofit organizations play an important role in addressing these needs, but charitable assistance alone cannot eliminate the broader financial burden of cancer. At SurvivingBreastCancer.org, financial assistance for people living with metastatic breast cancer is one component of our commitment to whole-person support, helping address nonmedical needs such as transportation, food, and essential household expenses. These forms of assistance may appear separate from medical treatment, but they are deeply connected to the experience of receiving care. A treatment plan does not exist independently of someone’s life. When we talk about access to cancer care, we must also talk about whether people can afford the everyday realities of getting that care. The Bigger Challenge: Connecting the Resources That Already Exist Perhaps the most important takeaway from this conversation was not any single gap but rather, the recognition that no organization, hospital, or healthcare professional can address every need independently. ABCD specializes in one-to-one emotional support. METAvivor focuses on metastatic breast cancer research, advocacy, and community. Unite for HER expands access to integrative therapies and supportive care. SurvivingBreastCancer.org brings together evidence-informed education, community, wellness programming, navigation resources, and financial assistance. These organizations have distinct missions, expertise, and models. And that is a strength. During the discussion, the leaders spoke openly about the importance of understanding where their organizations are uniquely positioned to contribute and where partnerships can better serve patients than duplicating existing programs. This approach requires a shift in how we think about the breast cancer support ecosystem. Rather than asking every organization to provide every service, we should be asking how to create more effective pathways between the services that already exist. That means building relationships across institutions, improving referral systems, sharing trusted resources, and making it easier for patients to understand their options. It also means recognizing that nonprofit programs require sustainable investment. Behind every free support group, educational webinar, peer mentor program, and patient assistance initiative are people, technology, training, infrastructure, and operational costs. Sustaining those services is part of sustaining access. If we want high-quality, reliable patient support to remain available, we must invest not only in individual programs but also in the organizations and systems that make those programs possible. What Should the Future of Breast Cancer Care Look Like? The future of breast cancer care will undoubtedly be shaped by scientific breakthroughs. New therapies, improved diagnostics, biomarker-driven treatment decisions, and advances in clinical research will continue to influence how breast cancer is treated. But medical innovation is only part of the equation. Progress must also be measured by how effectively people can access care, understand their options, manage symptoms, maintain quality of life, and find meaningful support. That requires a broader definition of comprehensive cancer care. The question is not whether every organization can do more, it is whether, together, we can build a system that works better for the people depending on it. Because the goal is not simply to create more breast cancer resources. It is to make the right resources easier to find, easier to access, and more meaningfully connected to the care people receive. That is the opportunity in front of us and it is a conversation worth continuing. At SurvivingBreastCancer.org, we believe patients and families deserve clear, evidence-based information that helps them ask informed questions and feel more confident in conversations with their medical team. Disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are personal and should be made in partnership with your oncology team.

  • FDA Approves TUKYSA (tucatinib) Combination as a New Maintenance Treatment Option for HER2-Positive Metastatic Breast Cancer

    What people with HER2-positive metastatic breast cancer should know about TUKYSA, Herceptin, and Perjeta. SurvivingBreastCancer.org Editorial EDUCATION | HER2+ Key Takeaways The FDA approval of TUKYSA (tucatinib) with Herceptin (trastuzumab) and Perjeta (pertuzumab) gives some adults with HER2-positive metastatic breast cancer a new chemotherapy-free maintenance treatment option after initial therapy. In the HER2CLIMB-05 trial, this combination helped people go longer before their cancer grew or spread compared with Herceptin and Perjeta alone. This treatment will not be right for everyone, but it may be an important option to discuss with your oncology team. The U.S. Food and Drug Administration has approved a new use for TUKYSA (tucatinib) in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) for people living with HER2-positive metastatic breast cancer (MBC) or unresectable locally advanced HER2-positive breast cancer after initial treatment. In plain language, this means that some people with HER2-positive metastatic breast cancer may now have a new chemotherapy-free maintenance treatment option after their first phase of treatment. This approval is important because it may help some people living with metastatic breast cancer go longer before their cancer grows or spreads. Let’s start with the basics: What is HER2-positive breast cancer? HER2 is a protein that helps cells grow. In some breast cancers, the cancer cells make too much HER2, which can cause the cancer to grow and spread more quickly. This is called HER2-positive breast cancer. HER2-positive breast cancer is often treated with medicines that specifically target HER2. These include drugs such as: trastuzumab (Herceptin) pertuzumab (Perjeta) tucatinib (TUKYSA) These are called HER2-targeted therapies because they are designed to interfere with the HER2 signals that help cancer cells grow. What was approved? The FDA approved TUKYSA (tucatinib) to be used with Herceptin (trastuzumab) and Perjeta (pertuzumab) as a maintenance treatment for people living with HER2-positive metastatic or unresectable locally advanced breast cancer after initial treatment. This approval applies after a person has already received initial treatment with: Herceptin (trastuzumab) Perjeta (pertuzumab) a taxane chemotherapy, such as paclitaxel (Taxol) or docetaxel (Taxotere) and their cancer has grown or progressed during that first phase of treatment. What does “maintenance treatment” mean? Maintenance treatment is treatment given after an initial treatment has helped control the cancer. We can think of it this way: The first phase of treatment is often used to get the cancer under control. If the cancer is shrinking, stable or responding to the treatment, maintenance treatment may be used to help keep the cancer controlled for as long as possible. For HER2-positive metastatic breast cancer, maintenance treatment often includes Herceptin (trastuzumab) and Perjeta (pertuzumab). This new approval adds TUKYSA (tucatinib) to that maintenance approach for eligible patients. Why is this approval important? In the Phase 3 HER2CLIMB-05 clinical trial, people who received TUKYSA (tucatinib) with Herceptin (trastuzumab) and Perjeta (pertuzumab) went longer before their cancer grew or spread compared with people who received Herceptin and Perjeta without TUKYSA. The study found: People receiving the TUKYSA combination had a median of 24.9 months before the cancer grew or spread. People receiving Herceptin and Perjeta without TUKYSA had a median of 16.3 months before the cancer grew or spread. This means the TUKYSA combination added a median of 8.6 more months without disease progression. The treatment reduced the risk of cancer progression by about 36% in the study. What does “progression-free survival” mean? You may see the phrase progression-free survival, often shortened to PFS. Progression-free survival means the amount of time during and after treatment that the cancer does not grow or spread. It does not mean the cancer is cured. It means the treatment helped keep the cancer controlled for a period of time. In this trial, the TUKYSA combination helped people go longer before the cancer grew or spread. Is TUKYSA (tucatinib) chemotherapy? TUKYSA is not traditional chemotherapy. TUKYSA is an oral targeted therapy. It is a pill that targets HER2, a protein involved in the growth of some breast cancer cells. Pfizer describes TUKYSA as an oral HER2 tyrosine kinase inhibitor. Herceptin and Perjeta are also HER2-targeted treatments, but they are given differently. They may be given through an IV or as part of a fixed-dose injection option, depending on the treatment plan. This approval is being described as a chemotherapy-free maintenance option because it may allow eligible patients to continue HER2-targeted treatment after initial chemotherapy without staying on traditional chemotherapy during the maintenance phase. Who might this apply to? This approval may apply to people with: HER2-positive metastatic breast cancer HER2-positive unresectable locally advanced breast cancer no cancer progression after initial treatment with Herceptin, Perjeta, and a taxane chemotherapy Your oncology team can help determine whether this treatment is appropriate based on your diagnosis, prior treatment, cancer behavior, side effects, other health conditions, and personal goals. What side effects should patients know about? Pfizer reported that the most common side effects in the HER2CLIMB-05 trial included diarrhea, muscle and joint pain, liver-related lab abnormalities or liver toxicity, nausea, fatigue, rash, and vomiting. What should I ask my oncology team? If you are taking or considering TUKYSA, ask your care team: Am I currently in the induction or maintenance phase of treatment? What does maintenance therapy mean in my treatment plan? Would TUKYSA be an option for me? What are the possible benefits of adding TUKYSA? How will my liver function be monitored? What should I do if I develop diarrhea? What side effects should I report right away? How will we know if the treatment is working? How often will I need bloodwork? Could this interact with any other medicines I take? Are there reasons this treatment may not be right for me? How does this option fit with my goals and quality of life? At SurvivingBreastCancer.org, we believe patients and families deserve clear, evidence-based information that helps them ask informed questions and feel more confident in conversations with their medical team. Disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are personal and should be made in partnership with your oncology team.

  • Breast Cancer Immunotherapy: Latest Advances and Treatments

    Learn the latest in immunotherapy for breast cancer. Checkpoint inhibitors now come with years of survival data behind them, and cellular therapies point toward an even more personalized future. SurvivingBreastCancer.org Editorial EDUCATION | IMMUNOTHERAPY Key Takeaways Immunotherapy helps the immune system identify and attack breast cancer cells. Pembrolizumab continues to improve long-term outcomes for some people with triple-negative breast cancer (TNBC). New antibody-drug conjugates give oncologists more ways to treat advanced and metastatic disease. Researchers are studying CAR T-cell therapy and other personalized treatments for breast cancer. Biomarker testing can reveal whether immunotherapy or targeted therapy may fit your diagnosis. Your oncology team can explain how the latest breast cancer treatments apply to your individual care plan. A breast cancer diagnosis brings a flood of new vocabulary, and immunotherapy often tops the list of confusing terms. Put simply, immunotherapy trains your immune system to recognize and attack cancer cells, rather than relying solely on chemotherapy or radiation. For individuals and loved ones navigating treatment decisions in 2026, several genuine breakthroughs deserve attention. Checkpoint Inhibitors Keep Proving Their Worth Cancer cells can sometimes avoid detection by using proteins that act as “off switches” on immune cells. Immune checkpoint inhibitors block those signals, allowing the immune system to respond more effectively. According to the National Cancer Institute, pembrolizumab, sold under the brand name Keytruda, remains the only immunotherapy drug specifically approved to treat breast cancer. Doctors generally use it in combination with other medications rather than on its own. Seven-year follow-up data from the KEYNOTE-522 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showed encouraging results: pairing pembrolizumab with chemotherapy before surgery, then continuing it afterward, improved both distant disease-free survival and overall survival in high-risk, early-stage TNBC patients. That long-term data matters enormously: it shows oncologists and patients that the benefit holds up not just in the months after treatment, but years later. Researchers selected TNBC for early immunotherapy trials because this subtype tends to respond better to immune-based approaches than hormone-receptor-positive cancers do. If you or a loved one has been diagnosed with TNBC, ask your oncology team directly whether checkpoint inhibitor therapy fits your treatment plan. Antibody-Drug Conjugates Pair Up With Immunotherapy Antibody-drug conjugates, or ADCs, deliver chemotherapy directly to cancer cells while sparing healthy tissue. In 2026, these drugs made real strides in metastatic TNBC. The FDA approved Dato-DXd for metastatic TNBC patients who don’t qualify for immunotherapy. The combination of Dato-DXd and a newer ADC called iza-bren improved both progression-free and overall survival compared with standard chemotherapy. Oncologists increasingly combine ADCs with immunotherapy drugs, giving patients more options when a single approach falls short. Cellular Therapies Enter the Picture CAR T-cell therapy has transformed treatment for certain blood cancers, and researchers are now testing it for breast cancer, too. Early-phase trials target antigens such as HER2, ROR1, MUC1, mesothelin, and B7-H3. These trials remain in their infancy, and scientists still face real obstacles, including finding antigens unique enough to breast tumors and overcoming the tumor’s ability to suppress immune attacks. Keep an eye on this research; it represents one of the field’s most promising long-term directions. A New Kind of Targeted Drug Joins the Toolkit May 2026 brought approval of vepdegestrant, sold as Veppanu, the first-ever approved PROTAC protein degrader, for patients with ESR1-mutated, hormone-receptor-positive, HER2-negative advanced breast cancer. While not a traditional immunotherapy, this drug works alongside immune-based treatments in many individuals’ broader care plans and signals how quickly the treatment landscape keeps shifting. What This Means for You Every advance above shares a common thread: oncologists increasingly combine tools rather than relying on any single treatment. Immunotherapy, ADCs, targeted therapies, and even AI-driven screening now work together to catch cancer earlier and treat it more precisely. Treatment jargon can be confusing. Bring a list of questions to every oncology appointment, and don’t hesitate to ask your care team to explain terms in plain language. Ask specifically whether biomarker testing, such as PD-L1 status, could open up immunotherapy options for your specific diagnosis. Breast cancer treatment in 2026 looks meaningfully different than it did even five years ago. Checkpoint inhibitors now come with years of survival data behind them, ADCs give oncologists new ways to target hard-to-treat cancers, and cellular therapies point toward an even more personalized future. Talk with your oncologist about which of these advances might apply to your situation, and remember that research keeps moving forward every single month. Count On Us For additional support navigating your diagnosis, treatment decisions, and life after a breast cancer diagnosis, visit SurvivingBreastCancer.org, which offers programs and trusted educational resources on symptoms, testing, treatment options, surgery, and more, plus podcasts featuring professionals, advocates, and caregivers. Your support helps SurvivingBreastCancer.org continue providing knowledge, connection, and community to those impacted by breast cancer, every day, all year long. Note: This article is designed to provide general information and is not meant to replace professional medical advice. Always discuss your options with your healthcare provider. Watch on YouTube: How MBC Treatments Target Cancer Cells Read More: The Role of Hormones in Breast Cancer Understanding Your Pathology Report: A Comprehensive Step-By-Step Guide AI Advances in Breast Cancer Detection and Treatment On the Podcast: Breast Cancer Conversations Episode 202. Good News for Triple Negative Breast Cancer: A Vaccine and Hope for the Future Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Her Last Question, My Lifelong Mission

    By Eswar Shankar, Ph.D. COMMUNITY | POETRY Content warning: death and dying October 21, 2022: a day that changed my life forever. “Won’t I get a second chance?” Those were among the last words my wife, Gayathri, said to me. I was holding her hand during the last few minutes she was conscious, before she slipped into a coma. I watched the person I loved slowly leave me, and in those moments, my entire world changed. Until then, I was a cancer researcher. I studied cancer through the eyes of science molecular pathways, biomarkers, therapeutic targets, resistance, tumor biology, and treatment. But that day, cancer was no longer something I studied in a laboratory. Cancer was taking my wife away from me. I became a caregiver. And being a caregiver changed my entire paradigm. I began to see cancer differently. I began to understand the urgency behind every diagnosis, every delay, every unanswered question. I started asking myself: What if we could detect cancer earlier? What if we could identify the right biomarker before it was too late? What if we could understand who is going to progress before the disease becomes irreversible? And most importantly: What if our research could give another patient the second chance my wife was asking for? Four years have now passed since Gayathri left this world. The grief remains, but so does something else: a purpose that has continued to evolve. My experience as a caregiver has changed the way I think about cancer research. It has made me look beyond discovery alone and think about translation, interception, early detection, meaningful biomarkers, and ultimately, giving patients more time. Today, when I look at a tumor sample, I don’t see only cells. I see a person. I see a family. I see someone sitting beside a hospital bed, hoping for another treatment, another opportunity, another morning. Another chance. Gayathri asked me a question I could not answer. “Won’t I get a second chance?” I could not give her that second chance. But I carry her question with me every day. It has become part of my purpose as a scientist. Perhaps this is what caregiving ultimately taught me: Cancer research is not only about understanding cancer. It is about creating possibilities for people to live. Four years later, my science continues to evolve. My grief has become reflection. My reflection has become purpose. And my purpose is to help create the possibilities that, perhaps, could give another family the time that we were not given. For Gayathri. For every patient. For every family waiting for a second chance. October 21, 2022: a date I will never forget. Forever in my heart. Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Was it the Four Loko?

    By Sophie Pumphrey COMMUNITY | BREAST CANCER STORIES “I miss being normal,” I tell my therapist. I miss not having to deal with the fallout of breast cancer. I used to feel like I had no time to myself as a mom and full-time employee. Then I got cancer and added another role. Cancer Patient. Your initial introduction to this role, to use corporate speak, is like drinking from the fire hose. It requires excellent multitasking skills, like trying to seem normal at work while feeling the hot breath of mortality on your neck. And exceptional organization skills, like remembering to give all the teachers at preschool a holiday gift while contemplating major surgery, chemo, and radiation. When you get a diagnosis like cancer, your brain tries to reason and blame. What could it have been that caused this?! Breast cancer has been rising at an alarming rate in women under 40, and I’m sure there is research underway trying to pinpoint exactly what could be going on. But for the next few years while we wait for the result of their research, I am left wondering. Was it the Four Loko? For those of you who can’t remember (who can blame you), Four Loko was a malt beverage with caffeine. You may still see Four Loko in your local corner liquor store, but this is a weakened caffeine-free version. Original strength Four Loko, along with Sparks, paired very well with sweaty warehouse parties, punk shows in basements, and frat parties. Four Loko was a blip of time in my life, but what about the other blips, did they cause my cancer? Was it from swimming in an almost certainly polluted lake every summer from prepubescence until my late 20s? Was it the cigarettes I bummed outside of shows? Was it eating hot dogs for breakfast, lunch, and dinner on that camping trip with my friends? Of course, there are the regular culprits that run through my mind. Alcohol? Birth control? Processed foods? But those themselves don’t really tell the story of a life lived. Yes, I went water-skiing in the Ohio River next to barges filled with coal. Yes, I ate gas station fried chicken after a night of staying up late with my fellow 20-somethings. Yes, I did say yes to another beer. Yes! I’m very familiar with the keyboard warrior types. The type that would leave a comment here to say, “Yes! You did it to yourself!” There is a special kind of judgment that only someone hiding behind a keyboard can have. News outlets love to publish articles like “5 Ways to Prevent Breast Cancer” with prudent lifestyle choices like: exercise, don’t drink, don’t be stressed, eat less meat, and don’t smoke. I can imagine that there are people out there that adhere to these rules like a religion. Nothing bad can happen to you as long as you follow these 5 holy tenants. And for the rest of us scumbags, we got what we deserved. I’m not sure about you, but I wasn’t thinking about almost 40-year-old me when I was drinking a 40. I wasn’t all bad, though; I did cook at home. I did go to the gym and go jogging. I used aluminum-free deodorant. I drank seltzer instead of soda. And I ate a lot of salad. I posted my Four Loko question on my breast cancer online support group, and the comments that followed were an exposé on women who were out living life fully. One commented, “Once in college I accidentally spilled a little Ajax in the kofta that I served to my study group. That was what did it for sure.” Many commenters suggested that it could have been from putting phones in their bras when they didn’t have pockets. That thread went as far as to blame the patriarchy for their lack of pockets and therefore their breast cancer. Doctors hate this one weird trick to prevent cancer. Pockets! The comments were almost like a confessional of stupidity, and it warmed my heart. There was so much to blame. Like rolling cigarettes in toothpaste, having an older sister who punched you in the boob, getting nipples pierced, and being from Wisconsin. The post and the question struck a chord in a space that is often full of not-so-fun questions. What do I need to buy to be comfortable after my double mastectomy? Should I get nipple reconstruction? The side effects from this drug are wearing me down, is it worth staying on it? What happens if I don’t do chemo or take endocrine therapy? Is it coming back? The post-cancer diagnosis life is hard. Before the cancer diagnosis, I felt healthy. I didn’t feel sick at all. I had a lump that was kind of painful, but not at a level that made me very concerned. I was reassured countless times by my doctors that I was too young for breast cancer, and besides, I didn’t have the family history. Now, one double mastectomy and 15 rounds of radiation later, I’m taking endocrine therapy drugs that cause intense pain in my feet and hands, and I feel like I’m 100 years old. I’ve been thrown headfirst into medically-induced menopause. Yes, I have less estrogen than your grandma. I am so achy every time I stand up, I hobble for the first 10 or so steps. I get hot flashes, my hair is thinning out and my skin all over is dry as sandpaper. I’m. So. Tired. Don’t ask me if I’m irritable. I am on these therapy drugs for 10 YEARS, and I had the thought recently that my youthful painless days are numbered. By the time I get off these drugs, I’m going to be old and in pain again. These drugs aren’t prescribed only to torture me, though; doctors and science have saved my life. Even having the ability to reduce my risk of recurrence is a miracle that women of the past would have certainly wished for. Believe me when I say, I will gladly take the pain of being on endocrine therapy over certain death, and I would do it 100 times. I will push through the pain and work hard to stay on my medications. As grateful as I am for the medicine to prevent recurrence, I am not without complaints. The treatments for hormone-positive breast cancer are almost like they are designed to destroy your love life. If you have a partner, you’re up to your own devices on how to have sex with a withered, dry vagina. It’s your responsibility to figure that out. Your oncologist may not tell you about this side effect. “Have you tried coconut oil?” Coconut oil: the multi-tool of the wellness world. Moisturizer, hair mask, salad dressing, and apparently, marital aid. Does it reverse vaginal atrophy? No! But thank you to my radiation oncologist for the friendly suggestion. If you are dating, well, now you have to figure out when to tell someone you had breast cancer. The first date? The third? Do you tell someone you just started seeing, “By the way, I’m infertile, and also I might get cancer again and die. How’s your soup?” The cruelty never stops. So, we are left wondering. As other commenters on my support group post asked, “Was it because my favorite party trick was sticking two lit cigarettes in my nostrils?” “Because I got my nails done every three weeks?” “Was it because in college I carved a hole in my couch’s arm and made it into a giant bong using empty baby food jars?” “Because I wasn’t vegan?” “Because I didn’t love the lord?” The answer is yes, we did do this to ourselves. It was caused by our life decisions as much as it was by random bad luck. Humans do not live in a vacuum; we live out in the world in an environment that we can’t always control. Everyone I know is trying to do the right thing for their health. They drink the green juice, they fast, they try the keto diet and walk 10,000 steps a day. They think that if they do this or that, they will be protected from an early demise. But we are fragile, and sometimes fate intervenes. We want to use science and facts to find blame because blame feels safe. Blame is the answer to the unanswerable. But blame doesn’t change reality, and it does not make cancer go away. As a cancer patient, we are often a victim being blamed for something that we did not entirely cause. If you got lung cancer after decades working in a printing shop, is it your fault? Should you have found a better job? I’ve seen reports that say even sitting at a cushy desk job all day may cause rectal cancer. What could be the least cancery career? We live in reality and can’t 100% adhere to the perfect lifestyle. Even if we could eat 10 cups of blueberries a day and exercise 300 minutes a week, your cancer risk is never 0%. Biology is always a factor. One maladjusted cell and poof, cancer. At one unpleasant visit with my oncologist, she revealed to me that cancer is really only cured if you die from something else first. How uplifting! I can’t wait to put that on a bumper sticker with a pink ribbon. I see the narrative that cancer is preventable. It gives the illusion that we have control over our meat sack bodies in ways that we don’t. They can tell us that we have cancer but can’t say exactly what caused it. But, if I knew what caused it, would it make a difference? I wouldn’t be able to go back in time and take back the naughty things I did, and I would still be sitting here with menopause-induced insomnia and breast implants, and scars, and radiation tattoos and pain. It was never just from microwaving soup in a plastic bowl or loving the smell of fresh gasoline in the morning. It was life. Being alive may cause cancer. Being alive may also cause family, friends, or pets. Being alive may cause drowsiness, weird rashes, and grief. Being alive may cause love. Ask your doctor if Four Loko is right for you. Read More: The Role of Hormones in Breast Cancer Addressing the Unique Challenges of Breast Cancer in People Under 40 The Power of Knowledge (My BRCA Story) Breast Cancer and Fertility Navigating Relationships After a Breast Cancer Diagnosis Managing Fatigue During Breast Cancer Treatment Questions to Ask Your Doctor After a Breast Cancer Diagnosis On the Podcast: Breast Cancer Conversations Episode 299. The Messy Middle of Breast Cancer: Chemo, Surgery, Side Effects, and Survivorship Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Before and After: My Rare Breast Cancer Subtype

    By Melinda Stumpp COMMUNITY | BREAST CANCER STORIES There comes a moment when your life divides into before and after. For me, it was a shower on September 7, 2024. The water was running. Steam blurred the mirror. It was an ordinary morning until it wasn’t. I rinsed my hair and my hand paused. I felt a lump. I had breast augmentation at nineteen. I knew my body. At thirty-seven, I knew this was different. It was not panic. It was not fear. It was instinct. A steady, undeniable knowing. My GP told me it was nothing. He told me not to worry. But something inside me was louder than reassurance. Louder than dismissal. And here is the defining moment of my life: I listened to it. I asked for the mammogram prescription. I walked into the cold imaging room wearing a paper gown that never quite closes. The machine hummed. The technician adjusted angles. Silence stretched between images. Then the phone rang. Phones do not ring in those rooms for good reasons. Before anyone said a word, I knew it. On October 1, 2024, the first day of Breast Cancer Awareness Month, I was diagnosed with triple negative metaplastic breast cancer, a rare one percent subtype. The words were clinical. Aggressive. Limited data. I did what everyone did. I googled it! And what I saw looked like a verdict. Survival curves. Statistics. Very little that felt human. Sitting there staring at that screen, I felt the weight of those numbers. And then I felt something else. If this is what women see when they search, then we need to change what they see. Cancer could change my body, but it would not take my identity. It would not take my voice or my chance to contribute to research. Chemotherapy tested that promise. It stripped me down physically and emotionally. There is nothing glamorous about chemo. Humor became my armor. If I could laugh in the infusion chair, I could survive almost anything. Four months after finishing treatment, just as I was beginning to feel steady again, my house burned down. Not metaphorically. Literally. I stood outside watching flames swallow everything physical. Documents. Photos. The proof of who I had been. Smoke in the air. Sirens cutting through the night. A life reduced to ash in real time. For a moment, it felt like everything was being taken. And then something settled inside me. If I could survive cancer and stand here watching this, I could survive anything. People say I shouldn’t be here. That statistically, medically, situationally, the odds were not in my favor. But I am standing here. No evidence of disease. Alive after a fire that could have taken more than possessions. I do not believe in luck alone. I believe it is mentality. It is instinct. It is a community. It is people who show up. It is laughter when everything feels heavy. Triple negative metaplastic breast cancer is rare. But rare does not mean hope. Rare means we speak. Rare means we study. Rare means we refuse to let Google define our future. I am participating in research. I am building advocacy. I am choosing, for the rest of my life, to contribute to this subtype so that the next woman who feels that lump does not open her laptop and feel doomed. Statistics are data. They are not destiny. The most defining moment of my life was not the diagnosis. It was the decision. The decision to trust myself when I was dismissed. The decision to speak when the room was quiet. The decision to rebuild when everything burned. You can lose your hair. You can lose your home. You can lose the life you thought you were living. But you do not have to lose yourself. I trusted my instinct, and that choice is why I am still here. Read More: The Role of Hormones in Breast Cancer The Impact of Breast Cancer on Self-Image Scheduling Worry Time: A Technique to Control Your Anxious Mind On the Podcast: Breast Cancer Conversations Episode 308. Can a Blood Test Detect Breast Cancer Recurrence? Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Awakening After Cancer

    By Jessi Lord COMMUNITY | BREAST CANCER STORIES How cancer ended my lifelong habit of leaving myself There are myriad ways to experience an awakening. I don’t believe we have just one during our lifetime, but many moments when the life we’ve built can no longer contain the truth of who we are becoming. This is because we are living not only as bodies moving through the material world, but as souls continually remembering who we have always been. Some awakenings arrive as quiet, almost imperceptible whispers of recognition. Others come as seismic shifts shaking us awake in a way that alters the course of our life forever. But both provide energetic rememberings of who we have always been. What followed my breast cancer diagnosis was not just survival - it was an unraveling, a reckoning, and ultimately, an awakening. What I couldn’t have known was that breast cancer would uncover a life that had been waiting beneath the one I thought I was living. I thought breast cancer would ask everything of my body. I had no idea it would ask everything of my soul. I hadn’t yet realized that my body surviving a full year of treatment would only be the beginning of my healing and that I would spend the next year learning how to inhabit it again. I had faced my greatest fear while in active cancer treatment. I came to understand how I would get through the physicality of it because of the advice from a wise retired oncologist, who was a dear friend of my late mother’s. He was my first phone call after I received the pathology report from the diagnostic biopsy. I asked him to help me understand the biology of the cancer I had and my options for treatment. The report said that I had triple-negative breast cancer. Unlike many other breast cancers, mine wouldn’t respond to hormone therapy or other targeted treatments like surgery right out the gate. There were no alternative paths to weigh, no decisions between different medications. From the very beginning, the plan was six months of weekly chemotherapy and immunotherapy infusions, followed by surgery, and finally radiation. Most of us have seen the physical transformations that can happen during chemotherapy whether in the movies or in real life as so many of us know someone diagnosed with breast cancer. The hair loss, becoming nauseous and weak and frail, sitting for hours at a time in an infusion room. Yet, how would I be able to do it? After a career of treating thousands of cancer patients, the retired oncologist informed me with absolute certainty: “There is no better survivor than a young mother. This is not a fight,” he said, “this is about curing your cancer. Remember… this is not a sprint, this is a marathon.” Deafening silence and a tidal wave of awareness of what he was saying hit me straight in the heart. There it was - all the motivation that I needed accompanied by the undeniable necessity to dig deep for the endurance I would need for the year ahead. Because he was right. There is no stronger force of energy than the strength and determination of a young mother. I had a daughter to live for; I embodied that archetype. When treatment was all over and with each passing week, I found myself spending less time at the cancer center, surrounded by one of the most supportive communities that I have ever been a part of, and more time alone with myself. And as the noise of treatment quieted, something within me grew louder and impossible to ignore. I was feeling confused, lost, circling and spinning in my efforts to make it back home to myself after what I had just been through. I felt small whispers of a loss, of a grief; tears would flow uncontrollably, sometimes out of nowhere like on a drive to a dentist appointment. These small shifts of release in my nervous system gradually grew in intensity and scale and the need to express what I was feeling became louder. I had read deeply about trauma and had come to understand the ideas presented in The Body Keeps the Score, and how trauma is stored in the body. Throughout my life, I adapted to trauma by becoming exquisitely attuned to everyone else’s needs while growing increasingly disconnected from my own. Hypervigilance became my normal. My nervous system never truly believed it was safe, so I ran, exercised, numbed with substances, withheld joy, and silenced my own voice for fear that expressing it would cost me connection with, honestly, anyone. I certainly had no idea what I needed to regulate my nervous system and definitely had no idea how to express my wants and needs with words. During a somatics-based alcohol recovery program during COVID, I raised my hand in genuine confusion. “Wait,” I said. “What do you mean when you say regulation means feeling safe in your body?” The Zoom room grew quiet as I heard myself say the words that surprised me most: “I didn’t know that.” It was one thing to know I was entering a whole new chapter of healing trauma in my life. It was another thing to actually walk through it. I couldn’t wait for perfect clarity on how to begin this new chapter, so I reached for a familiar coping technique. I immediately went back to work at the tail end of treatment thinking that this is the normal thing to do. Check! I took everyone’s encouragement as confirmation that I was doing exactly what I should be doing. Check again! Boy, was I proud of myself for diving right back in! My first day of my new job was my last day of radiation! Go me! But in hindsight, I confused everyone else’s encouragement with my own readiness. It actually was not something I was ready for. I was beginning to recognize a deeply conditioned pattern within myself: I had made another major life decision based on what I believed I should do rather than what I actually needed. At this point, the bouts of uncontrollable crying were happening nearly daily. Usually I could get back to myself with breath, sound, grounding on the grass, and other somatic techniques I had learned. It wasn’t quite evident to me yet that there was something deep inside me loosening its grip on me. But I was able to verbalize that I hadn’t felt depression like this since I was a young teenager - some of the darkest and most emotionally traumatic times of my life. I could only describe it by saying: “I don’t know how to find my way back home to myself.” Every coordinate I had once used to navigate my life no longer pointed me home. I was struggling. My dysregulated nervous system escalated from being overwhelmed to an all-consuming chronic state. I could not settle. It felt as if every internal compass I had trusted suddenly stopped working. I kept searching for language, an analogy that might come close to explaining what I was experiencing. The comparison that came to mind surprised me. I almost dismissed it before I allowed myself to say it out loud. “I feel real compassion for veterans,” I heard myself saying. The words hung in the air while I found myself wondering if survivorship carried its own version of that impossible transition. “They go off to war,” I wailed to others. “They see life-changing devastation and experience incredible trauma and upon their return to civil life, they are told: ‘Thank you for your service!’ with the expectation to just navigate seamlessly back into society. Can you even imagine!?” I heard myself yelling. But, they couldn’t understand the shared psychological challenge of returning to ordinary life after an extraordinary experience that I was trying to describe. Despite having just escaped death, I was told something similar: “You must be so happy to get back to normal!” But every time I heard that, I could not believe it, not even for a second. What those around me didn’t understand (aside from my ‘breasties’ on a WhatsApp thread that we used to bare ALL the brutal details of navigating our cancer journeys) was that there is no going back to “normal.” There would be no normal. It simply did not exist. After I saw, endured, and felt all the physicality of being a cancer patient, what I was experiencing now was the emotional backlash, the PTSD of surviving breast cancer - the lonely, confusing work of finding my way home after an experience that had forever changed my internal landscape. I felt alone with those closest around me. I was having dark thoughts of what the point of life was. The trauma of the medical experience I had just survived was catching up with me; slowly sneaking up on me, quietly behind my back. I’d turn around to see what was there and it would freeze… and upon turning back around it would quietly leapfrog closer to me, anxiously reaching and grabbing for my energy to pull into its darkness. I called my doctor for pharmacological intervention. For a while, I could keep its relentless grip at bay. I could feel it rising, but I could still meet the world with composure. Until one day I couldn’t. It happened in my kitchen with my boyfriend standing just a few feet away. What unfolded is difficult to describe in ordinary language. The closest words I have are Eckhart Tolle’s. It felt like my pain body took over, as though something long buried had finally demanded to be felt. I entered a dissociative, panic-filled state unlike anything I had ever experienced. A wave of panic consumed me. My breathing became ragged. I was confused. My boyfriend later told me my eyes looked different - dark, almost vacant. I remember pleading with him to let whatever was happening run its course. I believed my body was doing something it had been trying to do for decades: release what it had carried for far too long. I remember very little of what I said that day. Only the overwhelming certainty that I could no longer outrun what had been living inside me. Whether it was trauma releasing through my body, a nervous system overwhelmed by everything it had endured, or both, I knew one thing with absolute clarity: this wasn’t only about cancer anymore. 16 months after my original diagnosis, I took a necessary retreat to step away from the demands of daily life. I spent my time focused on meditation, yoga, and a workshop on the art of future-making. The structure of the retreat allowed my nervous system to relax and helped me find the grounding and clarity I needed to see what must change in my life. As I began to gain this clarity, I felt the familiar pull of fear and the ego trying to keep me anchored in old, unhealthy patterns. That hook to remain in old unhealthy patterns is what the ego is very good at doing. When it senses that you are remembering who you have always been and are initiating any kind of move towards the seat of your soul, it bears down. Your ego will tell you to remain hidden from the world and will guide you to relapse into the toxic patterns of your suffering. This is because the ego’s greatest fear is your soul waking up. It takes immense courage to witness your ego’s thoughts without being consumed by them any longer. It’s not for the faint of heart to question the story you’ve been telling yourself. For most of my life, I allowed those false narratives to run my operating system even though for the past ten years I had been attending a Tibetan Buddhist sangha in my local community. I would dutifully go twice a week to hear dharma talks, meditate with the deities, learn about the true nature of my original mind, and practice remembering who I have always been. Despite that active spiritual practice, my ego would still interpret the motives of others as mean or harmful, my nervous system responding to their actions as if the emotional abuse I experienced as a child was occurring again. But the door to clarity was cracking open. I could hear my soul guiding me to step into this other way of being that I had dedicated my practice to. It was time I stepped into this frequency that I had always known in my wisdom mind. A place where I could open my heart, see the pure perception and recognize that truth reflected back to me. I could finally tell myself the story my heart and my soul had always known was true. I had learned to advocate for my physical needs while I was in medical treatment for cancer. I went into that journey being the best advocate that I could be for myself. It was very clear very early on that I would have to both advocate for myself and surrender to the experience and knowledge of my team of oncologists. But now I was coming face to face with the mental wounds from the cancer journey - and now the healing wasn’t about fixing what was broken. And healing wasn’t about becoming someone new. It was about becoming someone I had never been allowed to be. If I finally faced the emotional journey that cancer had uncovered, I knew it would lead me to the very roots of my trauma. It was there that I could finally apply the salve to old wounds - to lovingly tend to the little girl who had spent so much of her life believing she had to earn love by abandoning herself. In caring for her, I began learning what it meant to care for myself, to become whole. And with pure clarity, I now understood that it was only from that place of wholeness that I could truly be in right relationship with others. Once I understood that my greatest responsibility was no longer just advocating for my body, but for the little girl who had always lived within it, everything began to change. I wanted to show her that I was here now - that she would never again have to navigate the world alone. That together, we would build a life spacious enough for joy. And that, little by little, she could learn to let it in. This summer, she and I are traveling across the world together. We will sit among women devoted to healing, walk barefoot along the shoreline, and spend long days beside the ocean where she has always felt most alive. For the first time in my life, I am not trying to become someone else. I am simply becoming the safe place she has been waiting for all along. ​I am coming to terms with the hard truth that tending to my own needs affects others who were used to my self-abandonment. It will take courage to assert what I need, but I know it is the only way to refill my own cups and to maintain healthy relationships. I’ve realized that life after cancer is forcing me to stop surviving in the ways I did long before my diagnosis. Cancer stripped away my old coping strategies and exposed the ways I had learned to abandon myself. Now, as a 48-year-old survivor who navigated chemotherapy, immunotherapy, surgery, followed by radiation, and the menopause that came alongside, I am committed to structuring my life in a way that truly works for me. I used to think surviving cancer meant getting my life back. I know now that there was no life to go back to. For years I believed I was searching for myself. It turns out that she had been waiting patiently for me to come back and get her. Oh Mary, I finally get it, this is what I will do with my one precious life! Somewhere along the way, I had mistaken survival for direction. I wasn’t lost because I lacked a map. I was lost because I had spent so many years navigating by everyone else’s compass instead of my own. And perhaps that was the awakening all along - that cancer had ended my lifelong habit of leaving myself. Read More: Understanding Your Pathology Report: A Comprehensive Step-By-Step Guide The Role of Hormones in Breast Cancer The Impact of Breast Cancer on Self-Image How Cancer Trauma Can Impact Your Life and Ways to Move Forward EFT and Brainspotting: Complementary Therapies for Breast Cancer Recovery On the Podcast: Breast Cancer Conversations Episode 306. Can Breathwork & Ayurveda Support Healing After Breast Cancer? Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Mea Ola, My Life

    By Jayshree Mallaya COMMUNITY | POETRY I received this news five weeks ago. It’s no longer a memory, it’s a lived reality. My life changed, but I’m still the same. I have breast cancer, but cancer is not my name. I’m dealing with something that feels alien inside of me, something that became part of my reality. From outside looking in, it looks like I’m fine. From inside looking out, I know I will be fine. I’m not questioning, why did this happen to me? There’s no family history, so how can this be? Breast cancer. Yes, it happened to me. I’m learning to listen to my body differently. To understand what it needs and what it’s trying to tell me. There are questions between appointments. Things I remember afterwards. Things I wish I had asked. Things that made sense when the doctor explained them, but were harder to remember when I got home. There are moments of fear. And moments of clarity. But through all of this, I am still me. Still a woman. Still a partner, sister, friend. Still dreaming. Still building. Still believing this isn’t where my story ends. Somewhere between the appointments, the questions, the things I remember and the things I forget, I started thinking, there must be a way to hold onto some of this. A way to remember. A way to stay connected. To my care. To the people caring for me. To the people walking this journey with me. And to myself. That thought became Mea Ola. My Life. A companion that’s growing from what I’m living and learning every day. Because breast cancer happened to me. But my life still belongs to me. And if what I’m learning can help another woman understand a little more, remember a little more, or feel a little less alone, then something good can come from what happened to me. Mea Ola. My Life. Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Broken Crayons Still Color: When Survival Changes You

    By Nerissa Balland EDUCATION | COMPLEMENTARY THERAPIES Surviving cancer and processing the experience of cancer are two very different things. Medical teams prepare you for surgery. They prepare you for treatment, side effects, scans, and follow-up appointments. They do everything they can to help preserve your life. What very few people prepare you for is what happens after the immediate crisis begins to settle. Listen to Nerissa on the SBC podcast, Breast Cancer Conversations: Surviving Cancer Is Only the Beginning: How to Process What Comes After When treatment ends, everyone celebrates. The scans are clear. Friends tell you how strong you are. Family members are relieved. Life slowly begins moving forward. Yet many survivors discover that survival isn’t the same as feeling whole again. That was certainly true for me. I was five months pregnant when I was diagnosed with metastatic melanoma. Overnight, my world became appointments, surgeries, treatment decisions, and the uncertainty of whether I would live long enough to raise my children. When my dermatologist called to tell me the biopsy was malignant, my mind raced through every role I held—wife, daughter, artist, mother. But beneath all of those thoughts was something smaller and infinitely more fragile: a heartbeat. The heartbeat of the child I had fought years of infertility to conceive. In that moment, cancer wasn’t simply threatening my life. It challenged everything I believed about motherhood, identity, purpose, and the future I imagined for my family. Like so many people facing a life-threatening illness, my focus became singular: survive. My medical team gave me that chance, and I will always be grateful. What no one prepared me for was the emotional landscape waiting on the other side. Although my body was healing, I wasn’t returning to the woman I had been before cancer. One day I caught my reflection in the mirror and didn’t recognize the person looking back at me. That realization frightened me more than the disease itself because I understood I wasn’t simply trying to recover physically—I was trying to understand who I had become. Cancer changed my body. Survival changed my identity. Learning how to reconcile the two became the real work. I’m a professionally trained artist. Most people assume creativity naturally became my refuge. It didn’t. Years of training had taught me to focus on technique and whether something looked “good.” Even after cancer, I was still evaluating what I created instead of allowing creativity to become a place of curiosity. Everything changed when I participated in a facilitated creative experience where there was no expectation to make something beautiful. For the first time, process mattered more than product. That’s when I realized: Creativity wasn’t helping me process cancer. It was helping me process myself. Cancer was the catalyst. It changed the trajectory of my life, but it also awakened a journey I never expected to take—one of reconnecting with myself through creativity, reflection, and ultimately helping others do the same. I couldn’t stop wondering if I was alone. Over the next several years, I interviewed more than one hundred young mothers facing cancer. Those conversations became the foundation of my book, Canvas of Courage. While my own diagnosis was metastatic melanoma, approximately 80% of the women I interviewed—and nearly three-quarters of the stories featured in the book—were navigating breast cancer. Although every woman’s story was unique, the emotional themes were remarkably familiar. Identity had been disrupted. The future felt uncertain. Women carried fear, guilt, grief, hope, and the pressure to remain strong for everyone else. Time and again, I saw creativity emerge—not as artistic talent, but as a way of making sense of lives that no longer felt familiar. One woman held dance parties with her children during treatment. Another took “mental photographs” of the sky before treatment because she wanted to remember the last ordinary day before everything changed. Another knitted while waiting for scan results. None of these women were trying to become artists. They were trying to remain themselves. Those conversations eventually led me to therapeutic arts and the broader field of arts in health. I discovered that what I had experienced personally wasn’t unique. Around the world, hospitals, cancer centers, and community organizations were using creative expression to support reflection, emotional processing, coping, and meaning-making. Creativity wasn’t replacing medicine. It was addressing something medicine was never designed to do. Today, my work brings together therapeutic arts, evidence-informed practices, and reflective approaches to help people reconnect with themselves and rebuild identity and purpose after life’s most difficult experiences. People aren’t broken. They’re unprocessed. That doesn’t mean we’re flawed or need fixing. It means many of us are carrying experiences we’ve never been given the space to fully examine, express, understand, or integrate. I’ve watched women walk into workshops apologizing before we even begin. “I'm not creative,” they’ll tell me. I smile, because I’ve heard those words so many times before. An hour later, something has shifted. The room grows quiet. The pressure to make something beautiful disappears. More than once, someone has looked up and said, “I didn’t realize how much I needed that.” That’s why I often say, “Broken crayons still color.” As an artist, I find there’s something special about opening a brand-new box of crayons. Every color is perfectly wrapped. Every point is sharp. Untouched. But if you’ve ever sat beside a child making art, you know those aren’t the crayons they reach for forever. Eventually the wrappers peel away. The tips break. Some snap in half. And yet… They still color. Not despite being broken. Because they’re still crayons. Their form changed. Not their purpose. I believe the same is true for us. Cancer may change our bodies. Survival may change our identity. We may never return to the person we were before our diagnosis. But we are still capable of creating, loving, contributing, finding meaning, and beginning again. Because healing isn’t only about surviving. It’s about reconnecting with the parts of ourselves we thought were lost. We may color differently than we did before. But we still color. Read More: The Transformative Power of Art Therapy in Cancer Survivorship From Chords to Chemo and Back Again: Rediscovering My Inner Harmony Navigating Cancer Treatment With the Help of Energy Medicine Survivorship Care Plans: Life After Breast Cancer Treatment Scheduling Worry Time: A Technique to Control Your Anxious Mind Expressive Arts with SBC: YouTube Playlist On the Podcast: Breast Cancer Conversations Episode 310: Surviving Cancer Is Only the Beginning: How to Process What Comes After Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • AI Advances in Breast Cancer Detection and Treatment

    Artificial intelligence may help doctors detect breast cancer earlier, understand each diagnosis more clearly, and recommend more personalized care. SurvivingBreastCancer.org Editorial EDUCATION | BREAST CANCER TREATMENT Key Takeaways AI-assisted mammograms can help radiologists detect more breast cancers without increasing false alarms. New AI tools may help predict a person’s future breast cancer risk. Digital pathology can give doctors additional information when planning treatment. AI supports medical professionals rather than replacing their expertise. Careful testing, human oversight, and patient support remain essential. Healthcare changes rapidly, but few fields move as fast as artificial intelligence (AI) in modern medicine. As of August 2026, artificial intelligence has moved beyond experimental promise in breast cancer care. Stronger evidence shows that AI can help radiologists find cancer earlier, estimate future risk, and give oncologists more information when they plan treatment. Doctors still make the decisions, but AI can serve as an additional set of eyes to review complex images and clinical data quickly. AI-Supported Mammograms Are Finding More Cancers Earlier A Swedish study of more than 105,000 women found that AI-supported mammogram screening helped radiologists detect 29% more breast cancers than traditional screening. The AI-supported process detected about 81% of breast cancers, compared with about 74% using the standard approach. It found more cancers without increasing false alarms, which occur when a mammogram appears suspicious but follow-up testing does not find cancer. AI also reduced radiologists’ screening workload by about 44%, allowing them to spend more time reviewing the mammograms most likely to show signs of cancer. Women whose mammograms received AI support had 12% fewer interval cancers, or cancers diagnosed after a normal mammogram but before the next scheduled screening. Researchers also found fewer invasive, large, and aggressive cancers in the AI-supported group, suggesting that AI may help radiologists detect some serious breast cancers sooner. AI does not replace radiologists. Instead, it can act as an additional tool that helps them notice possible warning signs, prioritize higher-risk mammograms, and find some cancers sooner. AI May Help Predict Future Breast Cancer Risk New AI tools can examine subtle mammogram patterns that traditional risk assessments may miss. In July 2025, the Food and Drug Administration (FDA) granted Breakthrough Device designation to Prognosia Breast, a tool developed through Washington University School of Medicine in St. Louis. It uses mammogram images and a patient’s age to estimate the risk of developing breast cancer within five years. WashU Medicine reports that developers trained the model on tens of thousands of screening exams and found that it predicted risk more accurately than a standard questionnaire-based method. The designation does not mean the FDA has approved or cleared the tool. It allows an expedited review process. With further testing in diverse populations, AI-based risk scores could help doctors personalize screening, prevention, and follow-up care. Digital Pathology Is Supporting Treatment Decisions AI can analyze digital images of biopsy or surgical tissue alongside clinical information. In May 2026, the FDA cleared ArteraAI Breast for people with early-stage, hormone receptor-positive, HER2-negative invasive breast cancer. The tool estimates whether a patient has a low or high risk of cancer spreading to distant parts of the body. The score doesn’t select a treatment, but it gives doctors more information when discussing chemotherapy, hormone therapy, and other options. Early research also suggests that it may help identify some patients who could benefit from chemotherapy, although more evidence is needed. AI Is Connecting More Types of Medical Data Researchers are developing multimodal AI systems that combine medical images with other health information, such as pathology reports, laboratory results, medical histories, and clinical notes. By reviewing several types of information together, these tools may help doctors predict cancer outcomes, estimate the risk of recurrence, and determine which treatments may work best for individual patients. However, researchers still need to test and validate these systems carefully before doctors can use them widely in patient care. Human Oversight Still Matters Researchers continue to study whether AI works safely in everyday care. The large US PRISM trial will examine whether AI-assisted mammogram review improves cancer detection and reduces unnecessary callbacks. AI won’t replace mammograms, biopsies, or medical professionals. Instead, it may help care teams recognize important patterns sooner and make more personalized decisions. Hope Powered by Innovation and Community AI may help doctors detect breast cancer earlier, understand each diagnosis more clearly, and recommend more personalized care. However, even the most advanced technology can’t replace compassionate guidance, trustworthy information, or the reassurance of connecting with people who understand the breast cancer experience. Whether you’re newly diagnosed with breast cancer, navigating survivorship, living with MBC, or supporting someone you love, SurvivingBreastCancer.org helps bridge the space between medical care and everyday life. We provide programs, including virtual support groups, as well as trusted educational resources and podcasts featuring professionals, advocates, and caregivers. Your support helps SurvivingBreastCancer.org continue providing knowledge, connection, and community to those impacted by breast cancer, every day, all year long. This article is intended for educational purposes and is not a substitute for personalized medical advice. Treatment approvals, guidelines, and research continue to evolve. Always discuss testing, medications, side effects, and treatment decisions with your oncology team. Read More: Different Types of Breast Cancer Understanding Your Pathology Report: A Comprehensive Step-By-Step Guide Addressing Breast Cancer Recurrence in High-Risk Patients On the Podcast: Breast Cancer Conversations Why Are Women Still Waiting Months for Breast Cancer Answers? With Dr. Ryan Polselli

  • Staying Strong and Active Through Breast Cancer Treatment and Beyond

    By Tarah Markham COMMUNITY | BREAST CANCER STORIES Six months before I was diagnosed with stage 2 breast cancer at 38, I started working out. I wasn’t really a fitness person. I didn’t have a routine or any big goal. I just decided I wanted to feel better and started showing up when I could. At the time, it didn’t feel like a big deal. Looking back, it ended up being one of the most important things I did for myself. The Moment I Knew Something Was Off I found the lump myself in December 2024. It was one of those moments where you just know. It felt hard and it didn’t move. I remember thinking, this doesn’t feel right. I had seen someone share their story on Instagram before, saying that when you feel a lump like that, you just know. That stuck with me, and it was in the back of my mind in that moment. Still, part of me didn’t think it could be cancer. I was 38, healthy, with no family history, and two young boys at home who were just 6 and 3 at the time. When I went to my doctor, she thought it was probably a fibroadenoma because of my age and history. But she still sent me for an ultrasound and mammogram, which I’m now so grateful for. When they told me I needed a biopsy, I think deep down I already knew. But I was heading on vacation the next day, so I put it in the back of my mind and tried to enjoy the week away. I was diagnosed in January 2025, the day after I got home. When Everything Changed Once I had the diagnosis, everything moved quickly. Appointments, decisions, trying to understand what was next. At the same time, I had two young kids at home. Life didn’t slow down. School, routines, everything kept going, and I still had to show up as their mom every day while figuring out what I was dealing with. Because I didn’t need chemotherapy and didn’t really look sick, my husband and I decided not to tell them. It was something we thought through carefully, and it felt right for us. But we still wanted a way to mark what was happening. On the day of my lumpectomy, we had the kids release two balloons. We called them “Cecilia,” which is the name my husband and I gave my cancer. It was simple, but it meant a lot to us. It felt like a way to include them without having to explain everything. What Helped Me Get Through My treatment included a lumpectomy, a sentinel node biopsy, radiation, and tamoxifen. Through it all, one thing I kept coming back to was staying active. I continued strength training as much as I could. Some days it looked different. Some days it was lighter. But I kept showing up. It wasn’t about pushing myself or trying to prove anything. It just gave me something steady to hold onto. It reminded me that my body was still strong, even when everything else felt uncertain. I also worked with a naturopath to help manage side effects and support my body through treatment. Along with trying to eat well and prioritizing sleep, it all played a role in how I felt day to day. Nothing about it was perfect. It was just consistent. Looking Back Looking back, I really believe those habits made a difference. Not in a dramatic way, but in small ways that added up. I felt stronger going into treatment, and I think that carried me through it. It also changed how I approached recovery. I wasn’t trying to go back to who I was before. I was figuring out what came next and building something different. One Year Later I’ve been pretty private about my diagnosis. Only close family, friends, and work really knew. But coming up on one year since ringing the bell on June 17, I’ve been thinking about it more. Those milestones bring a lot back. I feel strong. I feel good. But I also realize there’s a lot about this part of the experience that doesn’t get talked about. You move forward, but you still carry it with you in different ways. What Stayed With Me If there’s one thing I would say, it’s this: Taking care of your body matters. Not in an extreme way, and not in a way that adds pressure. Just in a steady, realistic way. Moving your body. Eating well. Sleeping when you can. Giving yourself some structure when everything feels uncertain. For me, strength training started before cancer, but it became something I relied on through it and something I’ve carried with me after. I didn’t expect it to matter as much as it did. But it did. Read More: Exercise and Breast Cancer Recovery: A Safe and Empowering Guide to Staying Active Understanding Breast Cancer in Young Adults: A Journey of Hope and Resilience Breast Cancer and Heart Health: The Connection You Need to Know About Managing Fatigue During Breast Cancer Treatment: Tips for Conserving Energy The Role of Nutrition in Breast Cancer Recovery: Optimizing Your Diet for Healing 20 Sleep Hacks For A Better Night’s Rest A Disabled Clinical Psychologist’s 6 Tips for Living Well with Breast Cancer On the Podcast: Breast Cancer Conversations Episode 291: Breast Cancer Survivorship: Exercise, Nutrition, Sleep, and Support Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Cancer in COVID Times

    By Jill Rackham COMMUNITY | POETRY Cancer has given me another reason to remember the year twenty-twenty. When the world was told to stay at home, I was having hospital visits aplenty. Rules stated I had to attend lots of appointments on my own so my husband waited outside. Although the staff were always lovely, waves of emotion overcame me just like a tide. Mammograms, an MRI scan, ultrasounds and biopsies all happened so fast. Followed by surgery, monthly injections and infusions – I wondered how long my frequent hospital trips would last. It was so hard to keep walking through the hospital doors for each of these on my own. Having cancer in times of COVID meant so much suddenly became unknown. Several days before each surgery, in the hospital car park, a COVID swab was taken. Then I had to isolate, thankfully the result was always negative, so surgery was never forsaken. Days in hospital recovering from surgery and dealing with my thoughts, all felt so long. Not being able to have loved ones near to give me much needed support, did feel so very wrong. The surgeon would come to see me to explain how proceedings had gone. In the haze of anaesthetic it was hard to take information in, but I wouldn’t have been the only one... Life is now as we knew it before COVID came along with rules no longer in place. It feels unbelievable as I reflect, about all the changes we had to face. COVID definitely added to the intensity of this trauma of mine. I had to be braver and more resilient than I had in life at any other time! Thankfully for anyone starting this awful journey now. COVID’s impact I hope will not feel as big somehow. Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • What Nobody Told Me About Life After Breast Cancer

    By Corinne Nechalova, MA, LPCC COMMUNITY | BREAST CANCER STORIES I thought finishing treatment would be the hardest part. I was wrong – it was what came after that undid me. When I was diagnosed with breast cancer, it came with bumps and challenges and a later staging than originally anticipated. It was a long road to get through physically – and of course emotionally. So much, so fast, and I had to dig so deep. When treatment ended, everyone around me seemed relieved. And I was too. The surgeries were behind me. Chemo was over. The appointments were becoming less frequent. By all accounts, I had made it through the hardest part. I thought I would finally be able to relax. Instead, I felt terrified. Before cancer, I trusted my body without even thinking about it. I assumed tomorrow would look a lot like today. I was 40, married, building a career I loved, living a full and social life. I felt like I had so much ahead of me. I trusted that if something was wrong, I would know. But when I was diagnosed with cancer, overnight, that trust disappeared. What shook me wasn’t just the diagnosis itself. It was realizing that something so serious had been happening inside my body without me knowing it. The body I had always counted on suddenly felt unpredictable. Unsafe. Foreign. During treatment, I had a job to do: survive. There were appointments to get to. Decisions to make. Side effects to manage. I stayed focused on the next step in front of me. But when treatment ended, all the fear I had pushed aside seemed to catch up with me. And I had a completely different body to add to the equation. I was not the same mentally, emotionally, or physically. After treatment, every ache got my attention. Every new sensation felt like a question I didn’t want answered. Every follow-up appointment sent me spiraling. I kept waiting for the relief everyone talked about. It never came. At least not right away. What surprised me most was how disconnected I felt. Disconnected from my body. Disconnected from my old life. Sometimes even disconnected from the people I loved. Everyone else seemed to be moving forward. I felt like I was still standing in the middle of it, trying to figure out who I was now. I remember looking around and wondering why I couldn’t just be grateful and relieved. Why I couldn’t just move on. Why I still felt so anxious when treatment was over. For a long time, I thought something was wrong with me – like, really wrong with me. So I did what I had always done. I pushed through. I tried to stay positive. I tried to get back to normal. But normal wasn’t waiting for me. Cancer had changed me. Not only physically. Emotionally. Mentally. And underneath all the pushing through, I was angry at my body. I felt trapped. I didn’t know how to take care of myself anymore – because if cancer had happened, surely I must have been doing something wrong. Looking back, I can see that cancer didn’t create all of that disconnection. Some of it had been there long before my diagnosis. I had spent years pushing through exhaustion, ignoring my own needs, treating my body as something to manage rather than something to listen to. Cancer simply made it impossible to keep doing that. And yet my body had also fought for me. It had healed, tolerated, and persevered through things I didn’t know it could. I was still here. I was getting stronger. I was learning to live inside a body that had been through something frightening – trying to hold both of those things at once: the anger and the gratitude, the fear and the awe. I had guided people through exactly this kind of recovery for years. Apparently that doesn’t make you immune to needing it yourself. But I wasn’t ready to hold any of that yet. I just kept moving, kept pushing, kept trying to outrun what I wasn’t ready to face. I tried to structure and discipline my way back to normal. And the harder I tried, the more exhausted I became. What finally helped wasn’t forcing myself forward. It was slowing down. Getting curious about what I was feeling. Allowing myself to grieve. To feel the feelings, the emotions, and yes, all the new sensations that came after treatment. Somewhere along the way, I realized that surviving cancer wasn’t just about healing my body. It was also about rebuilding my relationship with it. I had to learn how to listen again – to pay attention to what my body needed and what it had been trying to tell me all along. Not from my thinking mind, but from somewhere deeper. I started noticing when I needed rest instead of pushing through. When something felt like a genuine no rather than fear. When my body softened toward something instead of tightening against it. These weren’t dramatic realizations. They were small moments of learning how to hear myself again. Slowly, that became the foundation for something I thought I had lost: trust. Not trust that nothing bad would ever happen again. Not trust that life would unfold the way I planned. But trust that I could be with what was here. Trust that I could truly care for myself. Trust that I could find my way forward, even without certainty. Trust that there was a new me and a new life ahead, even if it hadn’t unfolded yet. What I was really learning was how to stop abandoning myself. How to feel the difference between anxiety and intuition. How to recognize when my body was saying no before my mind caught up. How to actually receive support instead of managing everything alone. Healing didn’t happen all at once. It happened in small moments. The morning I noticed my hair growing back and stood in front of the mirror and felt something other than grief. The day I laughed so hard I forgot about cancer for a few minutes. The first time fear wasn’t the very first thing I thought about when I woke up. The time I could change clothes and like what I saw and move my body and feel free. The changes that followed were bigger than I expected. I left my marriage. I changed my career. I overhauled the way I lived and the way I related to myself and others. None of it was easy. All of it was necessary. Little by little, life started returning. Not the life I had before, but a different life. One I never would have chosen, yet one I have learned to embrace. Today, fear still visits sometimes. I don’t think it ever completely disappears. But it no longer runs my life. If you’re in that strange space after treatment – wondering why you’re still anxious, still grieving, still waiting to feel like yourself again – I want you to know something. You are not doing survivorship wrong. Nothing is wrong with you. The fear makes sense. The uncertainty makes sense. But healing isn’t only about learning to live with fear. It’s also about learning how to come back to yourself. To your body. To your life. To the parts of you that were there all along, waiting to be heard. And that is possible too. About the author: Corinne Nechalova is a therapist, breast cancer survivor, and founder of Rise Reimagined, a program supporting women through the emotional and psychological recovery that happens after treatment ends. She is based in the Twin Cities. Learn more at corinnenechalova.com. Read More: The Psychological Impact of Breast Cancer: Strategies for Coping How Cancer Trauma Can Impact Your Life and Ways to Move Forward Scheduling Worry Time: A Technique to Control Your Anxious Mind Breast Cancer in Young Women: Common Questions Answered Navigating Relationships After a Breast Cancer Diagnosis Survivorship Care Plans: Life After Breast Cancer Treatment Grit and Grace On the Podcast: Breast Cancer Conversations Episode 299: The Messy Middle of Breast Cancer: Chemo, Surgery, Side Effects, and Survivorship with Jessica Thomas Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Survivorship Care Plans: Life After Breast Cancer Treatment

    Completing breast cancer treatment marks the transition into survivorship—a phase where individuals navigate life beyond active treatment. Survivorship care plans play a pivotal role in addressing post-treatment needs, monitoring health, and promoting overall well-being. Understanding Survivorship Care Plans A survivorship care plan is a comprehensive document that outlines a roadmap for post-treatment care. It provides a personalized summary of treatment received, potential side effects, recommendations for follow-up care, and strategies for maintaining health. Components of Survivorship Care Plans Treatment Summary: A detailed record of therapies, surgeries, and medications received during the course of treatment. Follow-Up Care Guidelines: Recommendations for ongoing screenings, diagnostic tests, and monitoring schedules. Long-Term Effects and Concerns: Information about potential long-term side effects or health risks post-treatment. Health Promotion Strategies: Suggestions for maintaining a healthy lifestyle, including diet, exercise, stress management, and smoking cessation. Supportive Services and Resources: Referrals to support groups, counseling, survivorship programs, and other resources. Life During and After Breast Cancer Treatment Physical Well-being: Regular follow-up appointments aid in monitoring for any recurrence or long-term side effects. Focus on maintaining a healthy lifestyle with regular exercise, a balanced diet, and adequate sleep. Emotional and Psychological Adjustment: Embrace emotional resilience by seeking support, joining support groups, or seeking counseling if needed. Coping with fears of recurrence or uncertainties about the future through mindfulness and acceptance. Addressing Long-Term Effects: Be aware of potential long-term effects of treatment, such as lymphedema, cognitive changes, fatigue, or menopausal symptoms. Seek medical advice and adopt coping strategies to manage these effects effectively. Empowerment through Self-Advocacy: Be an active participant in your health by understanding and advocating for your post-treatment care needs. Communicate openly with healthcare providers about concerns or questions. The Role of Survivorship Care Plans Facilitating Continuity of Care: Serve as a roadmap for ongoing care, ensuring a seamless transition from active treatment to survivorship. Empowering Patients: Offer patients the tools and information needed to take control of their health and well-being. Promoting Health Surveillance: Facilitate regular screenings and surveillance to detect any recurrence or new health issues early. Conclusion: Embracing Life Beyond Treatment Survivorship care plans are instrumental in guiding individuals through life after breast cancer treatment. Embracing survivorship involves addressing physical, emotional, and psychological well-being while staying proactive in monitoring health. Empowering oneself with knowledge, support, and regular follow-up care lays the foundation for a fulfilling life beyond breast cancer treatment.

  • Advocate for Yourself

    By Brookshire McDonald COMMUNITY | POETRY Be your own advocate You must do. Healthcare workers are great But overworked, too. Don’t accept “no news is good news” ‘Cause that’s not always so. You need to receive an answer “From the get go.” Life expectancy has increased Causing more older folks on earth, And referrals to specialists Has increased since birth. Appointments are taken For doctors galore Making the wait time A month or more. Adding your name to a call list Is sometimes a thing; But don’t hold your breath For a possible ring. Make the call yourself Every day or two To check on cancellations To find room for you. Make your case By saying you feel worse; But don’t jinx yourself By calling the hearse. Some offices get tired Of your calling so much; So by magic they have an opening Right before lunch! Don’t forget a second opinion Is always a good thing Even tho’ it’s another office You must continue to ring. It’s your body, So show it good care. It means more to you Than others anywhere! To be counted in the life expectancy numbers this year Be your own advocate To release all fear!! Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • I Chose to Move

    By Beth Krasemann COMMUNITY | BREAST CANCER STORIES In May 2023, I went on a run and a dog bit me! I went to a doctor to have it checked out and I asked for an order for a mammogram, as I had not had one since before Covid. The mammogram revealed a fairly large tumor–I was in shock as I had no symptoms, pain, or indication that a 8 centimeter tumor was embedded in my left breast. A needle biopsy and pathology analysis revealed I had triple positive breast cancer; I had positive receptors for estrogen, progesterone, and HER2. The cancer had spread to lymph nodes, so a treatment plan was crafted. Later studies put me at stage 2. As I navigated those frightening opening days and weeks, I made a decision I would not stop moving. I ran, hiked, swam, mountain biked, road biked, gravel biked, skied uphill, skied downhill, Nordic skied, kayaked, windsurfed, sailed, climbed mountains, wrote a book, taught high school history, coached ski mountaineering, traveled, and raced in many different events through 18 months of breast cancer treatment—20 rounds of chemo, 28 rounds of radiation, and a mastectomy. I used movement as medicine; I exercised on average 900 minutes a week, far above the 150 minutes recommended by the American Heart Association. I believe movement is the fourth pillar of cancer treatment. In the middle of treatment, I completed one of the most challenging ski mountaineering races in the United States: the Power of Four in Aspen, Colorado, with my son Daniel by my side. My answer to the absurdity of the diagnosis and treatment was to move. I grew up with three older brothers and very active parents who instilled in the family a passion for movement. We spent vacations skiing or backpacking in the mountains and all four of us played a range of sports growing up. After competing as a college soccer and track runner, I continued to pursue physical fitness as a runner and biker in my adult life. So when the cancer diagnosis arrived, I made a deliberate decision to not stop moving. I would not let cancer steal my love of fitness and adventure. It did not matter the pace or how; I simply needed to move my body, every day. The “red devil chemo” (doxorubicin) made running really hard, but I kept at it. I turned to skiing in the winter months as my main focus of movement. After my mastectomy, I skied using only one arm! In the spring, summer and fall, I turned to the trails to run and bike. When I was outside moving, I did not feel like a cancer patient. I felt like a healthy and normal athlete. I wrote about my experience in my book 900 Minutes: Movement as Medicine. It recounts the ups and downs of anyone fighting cancer—or any other trauma. It demonstrates how exercise—in all its forms—serves, sustains, and nurtures us all. I dedicate my book to exercise, in all forms, and to the resilience of my body. I pushed it so hard and she always responded and made my fight through the treatment manageable. To truly mark the end of my treatment and on to what I call Beth 2.0, my husband and I climbed Mt. Kilimanjaro in June 2026. My story serves as a model of what is possible during breast cancer treatment. Now, let’s get moving! About the author: Beth Krasemann is the author of 900 Minutes: Movement as Medicine. More information: https://900minutes.com/ Read More: The Role of Hormones in Breast Cancer What is Breast Cancer Rehab? Exercise and Breast Cancer Lymphedema is a Chronic Condition & Why I Love Swimming On the Podcast: Breast Cancer Conversations Episode 214: The Benefits of Pilates for Breast Cancer Recovery Share your story, poetry, or art: https://www.survivingbreastcancer.org/submit-breast-cancer-story Connect with SurvivingBreastCancer.org Podcast Weekly Meetup Free Events

  • Mirrors

    By Elisa Herrera We walk through a hallway of mirrors, the same day repeating in each one— yet never looking the same. In one, the light is soft, the weight of things barely touches me. I pass through the moment as if it means nothing. In another, the glass darkens— the same scene bends inward, presses against my chest until I can hardly breathe. Nothing has changed— the room, the words, the silence— yet the mirror turns it heavy, turns it into something I cannot carry. I move from reflection to reflection, not realizing I’ve stepped into a different one. One tells me I’m okay. Another whispers: this is too much. And somewhere in between, there must be a mirror that shows things as they are— not softer, not crueler—just true. But until I find it, I keep walking this corridor, living the same life in a thousand different ways. Share your poetry: https://www.survivingbreastcancer.org/submit-breast-cancer-story SurvivingBreastCancer.org Resources & Support: Podcast Weekly Meetups Free Events

  • Decoding the PAM Pathway: What Your Biomarkers Mean

    PIK3CA. AKT1. PTEN. mTOR. What the PI3K/AKT/mTOR pathway means for breast cancer treatment — and the questions worth bringing to your next appointment. SurvivingBreastCancer.org. Editorial EDUCATION | BIOMARKERS Breast cancer treatment is becoming increasingly personalized, but that progress comes with an entirely new vocabulary. PIK3CA. AKT1. PTEN. mTOR. These terms may appear on a biomarker report or come up when an oncologist is discussing why a treatment stopped working, or what treatment might come next. Together, they are part of the PI3K/AKT/mTOR pathway, often shortened to the PAM pathway. Understanding this pathway will not tell you exactly how your cancer will behave, but it may help explain what is driving it, why biomarker testing matters, and whether a targeted treatment could be an option. For some people with breast cancer, changes within the PAM pathway can help cancer cells grow, survive, or become less responsive to treatment. Finding those changes through biomarker testing may help your care team identify a treatment designed to target what is driving the cancer. Key Takeaways The PI3K/AKT/mTOR, or PAM, pathway helps regulate how cells grow, use energy, and survive. Changes involving genes such as PIK3CA, AKT1, or PTEN can allow cancer cells to continue receiving growth signals. PAM pathway alterations are especially relevant in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Biomarker testing may identify an alteration that helps guide treatment, but blood and tissue tests do not always provide the same information. A negative liquid biopsy does not necessarily rule out a mutation. In some cases, testing tumor tissue may provide additional answers. Having an alteration does not guarantee that a targeted treatment will work. Treatment decisions also depend on previous therapies, overall health, side-effect risks, and personal priorities. Side-effect prevention and early management, particularly for high blood sugar, rash, diarrhea, and mouth sores, are an important part of treatment. What is the PAM pathway? The PAM pathway is one of the communication systems cells use to control growth, division, energy use, and survival. In a healthy cell, the pathway switches on when it is needed and quiets down when the job is complete. In some breast cancers, however, a mutation or another molecular change disrupts this process. The pathway may continue sending growth and survival signals even when it should stop. Several genes and proteins play important roles: PI3K helps begin and pass along signals that tell a cell to grow. PIK3CA is the gene that provides instructions for making one part of the PI3K protein. AKT carries growth and survival messages farther into the cell. mTOR helps regulate cell growth, metabolism, and protein production. PTEN helps slow the pathway down and acts as one of its natural brakes. When PIK3CA or AKT becomes overly active, or when PTEN no longer functions properly, the cancer cell may gain another way to grow and survive. WHY IT MATTERS Why does this pathway matter in breast cancer? Changes in the PAM pathway are found across different breast cancer subtypes, but they have become especially important in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. One of the most commonly discussed changes is a mutation in PIK3CA. A PIK3CA mutation can cause the PI3K protein to remain overly active, sending ongoing signals that encourage the cancer cell to grow. Alterations involving AKT1 or a loss of normal PTEN function can have a similar effect by activating other parts of the pathway or removing the signals that would normally slow it down. The PAM pathway may also play a role in treatment resistance. For example, a hormone receptor-positive breast cancer may initially rely heavily on estrogen to grow and respond well to endocrine therapy (also referred to as hormonal therapy). Over time, some cancer cells may begin using another signaling system such as the PAM pathway to continue growing despite treatment. Cancer cells can change over time and develop new ways to survive. That is one reason biomarker testing may need to be revisited when cancer returns or progresses. TESTING What is biomarker testing, and why is it important? Biomarker testing is different from testing for inherited cancer risk. A hereditary genetic test usually looks for changes you were born with such as certain mutations in BRCA1, BRCA2, or PALB2, among many others, that may be present throughout the body and passed through families. Tumor biomarker testing looks primarily for changes that developed inside the cancer cells. These are called somatic alterations. Most PIK3CA mutations found in breast cancer are somatic. This means they developed in the tumor and were not necessarily inherited from a parent or passed on to a child. Some people benefit from both hereditary genetic testing and tumor biomarker testing because the tests answer different questions. How is the PAM pathway tested? Testing may be performed using tissue from the tumor, from a blood sample, or both. A laboratory may test tissue collected during a biopsy or surgery. In some cases, previously collected tissue can be used, although a newer sample may provide a more current picture of the cancer. A liquid biopsy uses a blood sample to look for small pieces of tumor DNA circulating in the bloodstream. This is known as circulating tumor DNA, or ctDNA. Liquid biopsies are less invasive than tissue biopsies and may detect information released by cancer in different parts of the body. However, not every cancer releases enough DNA into the blood to be detected. A negative liquid biopsy does not always mean that an alteration is absent. If your liquid biopsy comes back negative, an important question to raise with your oncology team would be: “My blood test did not find a mutation. Could testing tumor tissue give us additional information?” TREATMENT What could a PAM pathway alteration mean for treatment? Finding a PAM pathway alteration does not automatically determine your next treatment. It does, however, provide another piece of information your oncology team can use when comparing options. Several medications target different parts of the pathway. Their FDA-approved uses currently focus primarily on specific groups of people with HR-positive, HER2-negative locally advanced or metastatic breast cancer. These medications are not interchangeable. Eligibility depends on the exact alteration, previous treatments, timing of recurrence or profession, one’s overall health, and other individual factors. Does having a mutation mean the treatment will work? No biomarker can guarantee that a medication will work. A biomarker may tell your care team that a treatment is more likely to help a particular group of patients. But every cancer is complex. A tumor may have several alterations and use more than one pathway to grow. The presence of a mutation also does not tell us exactly how long a treatment will work for one individual. Your care team will consider: The exact alteration identified Your breast cancer subtype Previous treatments How long earlier treatments controlled the cancer Where the cancer is located How quickly it is progressing Your overall health Diabetes, prediabetes, or other medical conditions Possible medication interactions Side effects and quality-of-life priorities Available clinical trials Biomarker testing can help personalize treatment, but it is one part of a much larger conversation. SIDE EFFECTS What side effects should patients know about? The PAM pathway is involved in normal functions throughout the body, including blood sugar regulation, cell growth, and metabolism. Blocking the pathway can therefore affect healthy cells as well as cancer cells. Side effects vary by medication, dose, treatment combination, and individual health. High blood sugar PI3K and AKT inhibitors can raise blood sugar, sometimes significantly. Before beginning treatment, your care team may check: Fasting blood glucose Hemoglobin A1C Current diabetes medications Personal or family history of diabetes Other factors that could increase your risk Blood sugar may need to be monitored closely after treatment begins. Contact your care team if you experience: Increased thirst Frequent urination Unusual hunger Blurred vision Headaches Weakness or extreme fatigue Confusion Having diabetes or prediabetes does not always mean that a pathway inhibitor cannot be used. It may mean that additional planning, monitoring, or support from an endocrinologist is needed. Mouth sores Mouth soreness or ulcers, sometimes called stomatitis, can occur with several pathway inhibitors. Depending on the medication, your team may recommend a specific mouth rinse or other preventive strategy. Do not assume that all mouthwashes are appropriate, since products containing alcohol may worsen irritation. Diarrhea Diarrhea can lead to dehydration and electrolyte changes if it is not controlled. Ask your team: When should I start an antidiarrheal medication? How many episodes should prompt a call? What should I drink or eat? When is diarrhea considered urgent? Rash Rash can occur with some PI3K and AKT inhibitors. Reporting it early gives your care team the opportunity to intervene before it becomes more severe. Contact your team about new itching, redness, pain, blistering, peeling, or sores involving the skin, mouth, eyes, or genital area. Other side effects Depending on the treatment, additional effects may include: Fatigue Nausea Decreased appetite Changes in blood counts Increased risk of infection Changes in liver or kidney laboratory results Inflammation involving the lungs Changes affecting the eyes This does not mean that every patient will experience every side effect. It means that having a clear monitoring and management plan matters. Managing side effects is part of treatment Side-effect management is not an afterthought. It is part of receiving cancer treatment safely. Addressing symptoms early may help prevent complications, reduce interruptions, and make it easier to remain on treatment when the medication is helping. Before starting a PAM pathway inhibitor, consider asking: What side effects are most common with this exact medication? Which symptoms require an immediate call? How often will my blood sugar and laboratory results be checked? Will I need to monitor my blood sugar at home? Should I meet with an endocrinologist before treatment? Will you recommend medications to help prevent rash or mouth sores? Are there foods, supplements, or medications I should avoid? Who should I contact during evenings or weekends? Does the PAM pathway matter in early-stage breast cancer? The pathway can be present and biologically important in early-stage breast cancer, but most established PAM-targeted treatment uses in breast cancer currently apply to locally advanced or metastatic disease. Finding a PIK3CA, AKT1, or PTEN alteration in an early-stage tumor does not automatically mean that a PAM pathway inhibitor should be added to treatment. Researchers continue to study whether these medicines could help prevent recurrence or improve outcomes in earlier-stage disease. Clinical trials are necessary to determine whether a treatment is both safe and beneficial in a new setting. What about triple-negative or HER2-positive breast cancer? PAM pathway alterations can also occur in triple-negative and HER2-positive breast cancers. However, finding an alteration does not necessarily mean that one of the currently approved PAM-targeted treatments is appropriate. Researchers are studying pathway inhibitors in different breast cancer subtypes and in combination with: Chemotherapy HER2-targeted therapies Endocrine therapy Immunotherapy Other targeted treatments A clinical trial may be an option for some patients whose tumor has a pathway alteration but who do not meet the criteria for an existing FDA-approved treatment. How might targeting the pathway improve outcomes? Biomarker testing may reveal a specific alteration that can be targeted with an available medication. Blocking the PAM pathway may help interrupt one of the routes cancer cells use to continue growing despite endocrine therapy. For some patients, combining endocrine therapy with a targeted treatment may help control cancer longer than endocrine therapy alone. Questions to ask your care team Consider bringing these questions to your next appointment: Has my cancer been tested for PIK3CA, AKT1, PTEN, and other actionable biomarkers? Was the testing performed on blood, tumor tissue, or both? Which genes were included in the test? If my liquid biopsy was negative, should tumor tissue also be tested? Could my cancer’s biomarkers have changed since my original diagnosis? Does my result make me eligible for an FDA-approved treatment? How does this option compare with the other treatments available to me? What benefit was seen in clinical trials for patients whose situation was similar to mine? What side effects should I expect, and what can we do to prevent or manage them? Will I need blood sugar monitoring or support from an endocrinologist? Is there a clinical trial targeting this pathway that may be appropriate for me? Can I have a copy of my biomarker-testing report? What This Means for Patients The science behind the PAM pathway is complex, but its relevance to patients is much more practical: it may help explain why a cancer is growing, why a previous treatment is no longer working, and whether another treatment could target a specific feature of the tumor. Most importantly, you deserve more than a list of unfamiliar letters on a laboratory report. Ask your oncology team to walk you through what was found, what was not found, and whether the results change your options.. Understanding the science does not mean carrying the responsibility for making these decisions alone. It means having the information you need to participate meaningfully in your care. ________ This article is intended for educational purposes and is not a substitute for personalized medical advice. Treatment approvals, guidelines, and research continue to evolve. Always discuss biomarker testing, medications, side effects, and treatment decisions with your oncology team. Funding from Celcuity helps SurvivingBreastCancer.org provide free, evidence-informed education to people affected by breast cancer. Sponsorship does not constitute an endorsement of any product, treatment, or company.

bottom of page